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“I am driven by two main philosophies: know more today 
about the world than I knew yesterday and lessen the 
suffering of others. You'd be surprised how far that gets you.”  
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1.1. Neurodegenerative diseases in modern society 
With the advances in medicine, public health and economic development, the life 
expectancy of the population has increased steadily over the last two centuries. Alongside 
the increase in average lifespan and a continuously aging society, a much higher incidence 
of neurodegenerative diseases takes place. Between the years of 1990 and 2015, the 
number of deaths decurrent from neurological disorders increased in dramatic 36.7% 
(Feigin et al., 2017). Several studies have shown that neurodegenerative diseases configure 
an important cause of disability, mortality, and lead to an important social and economic 
burden worldwide (Feigin et al., 2017; Oeppen and Vaupel, 2002; Riley, 2001; Tuljapurkar 
et al., 2000). 
Neurodegenerative diseases are a product of neuronal dysfunction and neuronal 
cell death in the central and/or peripheral nervous system, usually associated to protein 
misfolding, aggregation and, in many cases, inflammation and immune cell activation. That 
results in a progressive neurological pathology in affected patients (Bredesen et al., 2006; 
Glass et al., 2010; Ross and Poirier, 2004; Skovronsky et al., 2006). Among the most 
common neurodegenerative diseases, Parkinson’s Disease (PD) is the second most 
prevalent and fastest-growing neurological disorder. The number of affected individuals is 
expected to double in the next 20 years (Dorsey and Bloem, 2018; Feigin et al., 2017). 
Therefore, efforts into understanding the key pathogenetic mechanisms and the 
development of disease-modifying therapies are of fundamental importance and have 
been object of intense research recently. 
 
1.2. Parkinson’s Disease 
1.2.1. Parkinson’s Disease – history, epidemiology and etiology 
The first scientific record on PD dates from 1817. In James Parkinson’s “Essay on the 
Shaking Palsy”, the cardinal motor features of PD were described in a group of patients. 
The main symptoms related to the disease - which include resting tremors, rigidity, postural 
instability and bradykinesia/hypokinesia - remain the clinical hallmarks used in PD diagnosis 
to this date (Agid, 1991; Lees, 2007). Later on, it was shown that the motor dysfunctions 





in the nigrostriatal pathway  (Agid, 1987, 1991; Hornykiewicz, 1966). Besides the 
extrapyramidal motor dysfunction, patients present a number of non-motor symptoms 
that range from sensory abnormalities to autonomic dysfunctions, as well as sleep 
alterations, mood disorders, depression and cognitive decline (Agid, 1991; Dauer and 
Przedborski, 2003a; Lim et al., 2009). 
PD is the second most prevalent neurodegenerative disease worldwide, only after 
Alzheimer's disease (AD). It is an age-related disorder, affecting up to 2% of individuals aged 
over 60 years. For the age group between 85 and 89 years of age, PD is prevalent in up to 
3,4% of individuals in Europe (De Lau and Breteler, 2013; de Rijk et al., 2000). From 1990 
to 2015, the prevalence of PD more than doubled worldwide (Feigin et al., 2017). The 
majority of the cases is composed of the sporadic form of the disease, and around 5% of 
the cases comprise familial/autosomal cases. Several autosomal mutations linked to the 
development of the familial form of PD were identified in the last decades. Classical PD-
related mutations affect genes that include, for example, SNCA, LRRK2, PINK1, DJ-1, and 
parkin. Although familial cases present different pathogenetic mechanisms and a wider age 
span in their occurrence, there are several common mechanisms between those cases and 
idiopathic forms of PD. Those include oxidative stress, excitotoxic mechanisms, 
mitochondrial dysfunction and defects in protein handling, for example (De Lau and 
Breteler, 2013; Dexter and Jenner, 2013a; Johnson et al., 2019). 
The presence of proteinaceous inclusions called Lewy bodies (LB) in the brains of 
PD patients is one of the pathological hallmarks of the disease. LBs are intracytoplasmic 
inclusions majorly composed of the protein alpha-synuclein (αSyn), but also contain 
ubiquitin and neurofilaments (Spillantini et al., 1997). As previously mentioned, mutations 
in the αSyn coding gene (SNCA) are broadly linked to familial forms of PD. However, LBs are 
present in both sporadic and familial PD cases (Bendor et al., 2013; Polymeropoulos, 1997; 
Singleton, 2003). Moreover, these aggregates are not constrained to the affected 
dopaminergic neurons but found spread throughout affected brains (Braak et al., 2003; 
Spillantini et al., 1997). The pathological role of LB formation is not completely understood. 
While some studies suggest they might be a direct cause of death to the affected nerve 
cells, others hypothesize that these inclusions might be a reactive mechanism aiming to 





Jenner, 2013a; Lu et al., 2005; Olanow et al., 2004). Nevertheless, the formation of protein 
aggregates in both familial and sporadic forms of PD suggests that a defective protein 
handling machinery is a mechanism directly related to the pathogenesis of PD (Bendor et 
al., 2013). 
Neuroinflammatory mechanisms have also been broadly linked to 
neurodegenerative diseases, including PD. The presence of activated microglial cells in the 
substantia nigra of PD-affected brains was one of the first findings correlating 
neuroinflammation to PD (McGeer et al., 1988a). The main neuroinflammatory 
mechanisms in PD pathology include microglial activation, lymphocytic infiltration and 
astrogliosis (Hirsch and Hunot, 2009). A series of studies showed that a chronic 
inflammatory state contributes to the neurodegenerative processes in PD. The release of 
neurotoxic cytokines by glial cells likely extends the neuronal cell damage even further 
(Joers et al., 2017; Liddelow et al., 2017; Macchi et al., 2015). Markers of inflammation are 
reported to be present not only in the brain of PD patients but also in the periphery (Macchi 
et al., 2015). Furthermore, there is evidence for the contribution of inflammatory 
mediators to αSyn misfolding and aggregation (Gao et al., 2008). Currently, 
neuroinflammation is not only referred as a consequence of the neurodegeneration in PD 
but also as one of the possible primary causes to the progression of PD. 
Several environmental and genetic risk factors may predispose to the occurrence of 
PD (Dexter and Jenner, 2013a; Schapira and Jenner, 2011). Nonetheless, there is no 
canonical mechanism or pathway that would describe the exact pathogenesis of PD to date. 
Despite the several known mechanisms contributing to different aspects of PD pathology, 
recent studies in the field point to a multitude of primary causes that might differ between 
affected patients, suggesting that PD might not be configured as a single disease, but rather 
be a multifactorial syndrome with multiple pathogenic subgroups (Dexter and Jenner, 
2013a; Johnson et al., 2019). 
 
1.2.2. Pathophysiology and progression of PD 
PD patients present a chronic and progressive phenotype of motor dysfunction 





midbrain. The loss of pigmentation in one of the nuclei of the midbrain, the substantia 
nigra, was one of the earliest histological findings linked to PD (Trétiakoff, 1919), which 
was, later on, proved to be resultant from the degeneration of the neuromelanin-positive 
dopaminergic cells in that region (Marsden, 1983). A very prominent dopaminergic cell loss 
occurs in the nigrostriatal system, more specifically in the substantia nigra pars compacta 
(SNpc) (Figure 1A). Studies have shown that by the start of the clinical signs of PD, there is 
a dramatic reduction on dopamine levels in the striatum of the patients (up to 80% 
reduction), while only 30-50% of the dopaminergic cell bodies seem to be degenerated at 
that phase. Those findings suggest that a retrograde dopaminergic degeneration occurs in 
the nigrostriatal pathway, starting from the striatal pre-synaptic terminals of axonal 
projections, progressing to the cell bodies located in the substantia nigra. The severe 
deficits in motor control and initiation of voluntary movements observed in PD patients are 
intrinsically related to the degeneration of nigral dopaminergic neurons and the 
consequent dopamine depletion in the nigrostriatal system. (Braak et al., 2003; Burke and 
O’Malley, 2014; Dauer and Przedborski, 2003a; Schmidt and Kretschmer, 1997). 
The basal ganglia comprise a collection of subcortical nuclei that include the 
striatum (formed by the putamen and the caudate nucleus), the globus pallidus (internal 
and external parts), the subthalamic nucleus (STN) and the substantia nigra. These nuclei 
present extensive connectivity between each other and several other brain regions, 
forming complex neuronal networks that regulate motor functions in different levels. The 
anatomical organization of the motor circuit is illustrated in Figure 1B. In more detail, 
glutamatergic excitatory projections from the motor cortex reach the striatum (at the 
postero-lateral putamen), communicating with GABAergic neurons. These inhibitory 
neurons are involved in two distinct projection pathways - the so-called “direct” and the 
“indirect” basal ganglia signaling pathways. They encompass the connection of the striatum 
to other two basal ganglia nuclei: the internal globus pallidus (GPi) and the substantia nigra 
pars reticulata (SNpr). In the direct pathway, GABAergic striatal neurons make direct 
connections to the GPi and the SNpr, exerting inhibitory input to the neurons present in 
those nuclei. Upon activation, the direct pathway leads to inhibition of the neurons in the 
GPi/SNpr and subsequent excitation of the thalamus and the motor cortex, a loop that 





pathway, the putamen is primarily connected with the external globus pallidus (GPe) and 
the STN, which finally send projections to the GPi/SNpr regions. The GPe contains 
GABAergic inhibitory neurons, while STN neurons are glutamatergic. Upon stimulation, the 
striatal neurons belonging to the indirect pathway promote inhibition of the GPe and 
subsequent disinhibition of the STN, which finally leads to excitation of the GPi/SNpr nuclei, 
inhibiting thalamic/cortical regions and, consequently, suppressing motor activity. The 
antagonistic effects of these two pathways influence the output activity of the basal 
ganglia, regulating voluntary movement initiation and motor control (Forno, 1996; Obeso 
et al., 2000).The dopaminergic neurons present in the SNpc exert a key regulatory input to 
the motor circuit by innervating the spiny striatal neurons present in the putamen. Striatal 
neurons belonging to each pathway express a different type of dopamine receptor. 
Neurons that are part of the direct pathway express excitatory D1 receptors, while the 
indirect pathway contains neurons bearing inhibitory D2 receptors. Thus, the dopamine 
signaling in the nigrostriatal circuit produces dual effects on the motor circuit, promoting 
either the enhancement of the direct pathway or the suppression of the indirect pathway. 
In the parkinsonian state, the dopamine deficiency caused by the nigral neurodegeneration 
results in an impairment in both direct and indirect pathways, which ultimately leads to 
increased activity in the GPi and the SNpr. With that, excessive inhibition of the thalamus 
and the motor cortex takes place, progressively affecting motor control in PD patients  
(Forno, 1996; Obeso et al., 2000; Schmidt and Kretschmer, 1997).  
Figure 1. (A) Nigrostriatal projections - schematic representation. In a midbrain section of a 





by the presence of neuromelanin expressing dopaminergic neurons. Preserved striatal projections 
represented in red (thick lines); in the parkinsonians state (right side), a marked depigmentation is 
observed in the SNpc due to the degeneration of the dopaminergic neurons. A consequent 
disruption of the striatal projections is represented in red (thin/dotted lines).  (Dauer and 
Przedborski, 2003a), adapted. (B) Representation of coronal brain sections depicting the basal 
ganglia circuits (both in healthy and Parkinson’s Disease states). Thickness of lines indicates the 
strength of the connections. In the parkinsonian state, nigral degeneration leads to increased 
thalamic inhibition. DA: dopamine; GPe: globus pallidus externus; GPi: globus pallidus internus; 
SNpc: substantia nigra pars compacta; SNpr: substantia nigra pars reticulata; STN: subthalamic 
nucleus. (Calabresi et al., 2014; Dauer and Przedborski, 2003a), adapted. 
Furthermore, the basal ganglia present connections to a number of other brain 
regions. These include for instance the limbic system, prefrontal cortex, medulla oblongata 
and the pons. Hence, the PD pathology produces a series of nonmotor neuropsychiatric 
symptoms that are present in a majority of all PD cases (Braak et al., 2003; Dexter and 
Jenner, 2013a; Witjas et al., 2002). 
 
1.2.3. PD diagnosis and therapeutic alternatives 
The diagnosis of PD strongly relies on the clinical manifestation of the motor 
phenotype. Generally, the criteria considered for the diagnosis of PD are the presence of 
bradykinesia together with other cardinal features, such as muscular rigidity, resting 
tremor or postural instability and the absence of exclusion criteria (Postuma et al., 2015). 
Recently, neuroimaging techniques and biochemical tests with cerebrospinal and 
peripheral body fluids have been employed as additional evidence for differential 
diagnosis. However, PD misdiagnosis is still a major problem (Tolosa et al., 2006). 
Particularly, there is a strong need for better diagnosis at early stages, since PD patients 
start to display the first motor symptoms only when the dopaminergic neurodegeneration 
is already at an advanced stage (Kalia and Lang, 2015).  
Despite extensive studies on the mechanisms contributing to the 
neurodegeneration and disease progression in PD,  the exact pathogenetic events – 





understood. Allied to the late diagnosis, the limited regenerative capability of neurons in 
the central nervous system substantially hinder the development of causative treatment 
options. Although there are multiple and effective therapeutic options for PD, all currently 
available therapies for PD are symptomatic. The most common of them relies on the 
pharmacological replenishment of dopamine by oral or enteric administration of the 
prodrug L-3,4-dihydroxyphenylalanine, also known as levodopa (L-DOPA). L-DOPA 
administration is usually combined with drugs that prevent its peripheral metabolism, 
enhancing the bioavailability of this dopamine precursor before it crosses the blood-brain 
barrier. In spite of attenuating the symptoms, the treatment with L-DOPA presents a 
number of limitations and possible side effects. The majority of the patients on a long-term 
L-DOPA therapy experience loss of efficacy, drug-induced dyskinesia, fluctuations or 
toxicity by the drug. Other common adverse effects are progressive cognitive defects, 
depression and other neuropsychiatric dysfunctions (Connolly and Lang, 2014; Marsden, 
1994; Nutt et al., 1994) 
Due to the lack of effective therapeutic strategies for PD,  effort into understanding 
the pathogenic mechanisms in more detail and finding possible biomarkers for the disease 
would be of extreme importance, facilitating the early diagnosis and allowing the 
development of novel curative treatments for PD. 
 
1.3. Gene expression regulation and miRNA biology 
Recently, a number of studies showed that dysfunctions in the regulation of gene 
expression are critical to the development of brain diseases. Several studies have shown 
that non-coding RNAs (ncRNAs) are necessary for the development and survival of neurons. 
They are involved in a myriad of cellular mechanisms and of major importance for the 
homeostatic maintenance of cells. In addition, they have been shown to play a very 
important role in the pathogenesis of neurodegenerative diseases (Eacker et al., 2009; 
Galasso et al., 2010; Hebert and De Strooper, 2007; Roser et al., 2018a). 
Among the ncRNAs classes, miRNAs are by far the most studied species, and 
research has drawn substantial attention to the role of miRNAs in brain diseases in the last 





provide a widespread machinery of post-transcriptional regulation of gene expression by 
mechanisms similar to RNA interference, targeting multiple genes and a variety of 
pathways in health and disease (He and Hannon, 2004).  
 
1.3.1. Overview on epigenetics and miRNAs 
The number of studies concerning the epigenetic regulation of gene expression has 
increased dramatically in the last decades. The term “epigenetics” was initially introduced 
by Conrad Waddington in 1942, even before the first studies on structural and functional 
properties of genes were published. Waddington referred to an “epigenetic landscape” 
while postulating on the ways genetic information act systemically in order to produce a 
phenotype (Waddington, 1942, 2012). A modern definition for epigenetics was proposed 
by Riggs and colleagues, stating that epigenetics comprise “the study of mitotically and/or 
meiotically heritable changes in gene function that cannot be explained by changes in the 
DNA sequence” (Allen, 2015; Holliday, 2006; Riggs, 1996). To date, known epigenetic 
mechanisms include histone modifications, DNA methylation and ncRNAs. The latter class 
has been extensively studied in the context of CNS diseases (Bird, 2007; Fischer, 2014). 
NcRNA species are usually classified according to their nucleotide length: small 
ncRNAs present up to 200 base pairs, while species with over 200 base pairs are referred 
as long ncRNAs. Small ncRNAs are further subdivided into Piwi-interacting RNAs (piRNAs), 
small nucleolar RNAs (snoRNAs) and micro RNAs (miRNAs). miRNAs are processed from the 
transcripts of endogenous genes and comprise the most-studied class of ncRNAs. They 
exert a post-transcriptional regulation of gene expression, targeting mRNAs by base-pair 
complementarity. Upon binding to the 3’ untranslated regions (UTR) of transcripts, miRNAs 
are able to silence genes via translational repression or mRNA destabilization/degradation. 
Furthermore, miRNAs are involved in a number of important cellular and biological 
processes, including differentiation and development, cellular proliferation, homeostatic 
maintenance, hematopoiesis and inflammation. Disbalance in miRNA networks are linked 
to the development of a series of diseases, from cancer to metabolic and neurologic 
disorders  (Bartel, 2004; Berezikov et al., 2006; Fabian et al., 2010; Friedman and Jones, 





The coding sequences for miRNA species are located in both coding and intergenic 
regions, and they are processed either from introns or from exons after splicing. Mature 
miRNAs are encoded from genomic stem-loop precursors, presenting very short nucleotide 
length (between 17-24 nucleotides) (Bartel, 2004; Berezikov et al., 2006; He and Hannon, 
2004). A recent review refers to over 2,000 miRNA species already identified in humans, 
which are responsible for collective targeting and regulation of more than 60% of the genes 
from the human genome (Friedman et al., 2008; Hammond, 2015). A remarkable feature 
from miRNAs is that each mature sequence may target hundreds of targets mRNAs. 
Furthermore, individual genes can be targeted by several different miRNA species, creating 
a very complex regulatory network of gene expression that potentially affects thousands 
of genes (Friedman and Jones, 2009; Friedman et al., 2008). Those findings were confirmed 
in a number of important studies that employed transcriptomic and proteomic profiling 
approaches, indicating that translational repression by miRNAs encompasses an important 
mechanism of fine-tuning for protein expression at the cellular level (Baek et al., 2008; 
Elkan-Miller et al., 2011; Gillardon et al., 2008; Lim et al., 2005; Moraes et al., 2017). 
 
1.3.2. miRNA biogenesis and gene silencing 
The biogenesis of miRNAs takes place in the nucleus, and most of the described 
miRNAs are derived from the canonical biogenesis pathway (illustrated in Figure 2). Primary 
miRNA genes are transcribed by RNA Polymerase II enzymes into long precursor transcripts, 
the pri-miRNAs. Those long transcripts are then processed by the RNAse III enzyme known 
as Drosha, giving rise to long hairpin-looped miRNA precursors (pre-miRNAs). The cleavage 
by Drosha is dependent on the interaction with the DGCR8 class of proteins for the active 
binding to double-stranded RNA molecules (Han, 2004; Lee et al., 2003, 2004). The newly 
formed hairpin-shaped pre-miRNAs are then carried to the cytoplasm by the Exportin-5 
transporter (a process dependent on RAN-GTP binding proteins), to be further cleaved by 
another kind of RNAse III called Dicer. These interactions take place in the so-called 
processing (p-) bodies in the cytoplasm. The resulting oligonucleotides duplexes present 
already short length, typical from miRNAs. One of the strands is then converted into the 
mature form of the given miRNA, while the exceeding strand is usually degraded. Dicer also 





proteins - and this interaction is fundamental to the silencing activity of miRNAs. More 
specifically, the AGO2 subtype of these proteins is exclusively present in active miRNA 
silencing complexes in humans. Upon assembly, miRNA-AGO2 complexes finally turn into 
the active RNA-induced silencing complex (RISC) and are able to target mRNAs by 
nucleotide complementarity (Bartel, 2004; Chendrimada et al., 2005; Gregory et al., 2005; Haase 
et al., 2005; Kim et al., 2009; Kulkarni et al., 2010).  
Figure 2. Canonical miRNA biogenesis pathway - schematic representation. Inside the nucleus, 
miRNA coding genes are transcribed into pri-miRNA transcripts, which are further processed by an 
RNase type III (Drosha) associated with DGCR8.  The resulting looped Pre-miRNAs are exported to 
the cytoplasm by RAN-GTP dependent exportin-5 and cleaved by Dicer, resulting in a duplex miRNA 
molecule. Upon assembly with AGO2 proteins, the RNA-induced silencing factor (RISC) is formed 





1.3.3. The role of miRNAs in neurodegeneration and PD 
miRNAs are widely expressed over all the different types of human tissue, but 
astonishing 70% of all miRNAs are expressed in the human central and peripheral nervous 
system (Nowak and Michlewski, 2013). Numerous studies have shown that miRNAs 
contribute to a variety of biological processes in nervous tissue, including neurogenesis and 
differentiation, neuronal development, maintenance, morphogenesis and regulation of 
programmed cell death (Chen and Qin, 2015; Kapsimali et al., 2007; Narayan et al., 2015; 
Schratt et al., 2006). For their absolute importance in maintenance and function of 
neuronal cells, defects in miRNAs networks might lead to a series of pathogenic processes 
in the brain. 
Alterations in miRNA expression have been linked to a number of 
neurodevelopmental and neurodegenerative diseases (Sun and Shi, 2015).  For example, 
the expression levels of several miRNAs were found altered in the brains of AD and 
Huntington's disease (HD) patients (Quinlan et al., 2017; Shioya et al., 2010; Zovoilis et al., 
2011). Similarly, several described alterations in miRNA expression are also reported in PD, 
both in nervous tissue and in peripheral fluids of affected patients (Mouradian, 2012; Roser 
et al., 2018b). A couple of studies found deficient levels of miR-133b in the midbrain of both 
PD patients and from mouse models of PD  (Hebert and De Strooper, 2007; Kim et al., 2007). 
Another important study found alterations in the levels of miR-34b/c in several regions of 
PD-affected brains. By manipulation of the levels of these miRNAs in vitro, researchers 
were able to mimic impairments in mitochondrial functions and oxidative stress, 
pathomechanisms believed to be crucial for the development of PD (Miñones-Moyano et 
al., 2011). Furthermore, studies identified two specific miRNAs regulating the expression 
of αSyn (namely, miR-7 and miR-153) in vitro. Interestingly, the former has been found 
altered in the striatum and substantia nigra of PD patients, as well as in murine models of 
PD (Doxakis, 2010; Farh, 2005; Junn et al., 2009). In addition, target prediction and 
enrichment analyses identified several miRNAs that might regulate PD-associated genes, in 
regard to autophagy and lysosomal related pathway. Those miRNAs species include miR-
98, miR-124, miR-142, miR-130, and miR-204 (Jegga et al., 2011; Junn et al., 2009). 
Another important aspect of miRNA regulation in PD is the fact that they are 





study in the field showed that the deletion of the enzyme Dicer – pivotal for the biogenesis 
of miRNAs – led to reduced neurogenesis and a strong dopaminergic degeneration in vitro. 
Similarly, when analyzing a murine model presenting a conditional Dicer knockout, a 
marked and progressive dopaminergic neurodegeneration is observed in the midbrain of 
the animals, reaching up to 90% of dopaminergic cell loss in up to 6 weeks of age. 
Remarkably, the phenotype is significantly rescued when transfecting Dicer-deleted 
cultured neurons with midbrain-derived small RNAs (<200bp), but not with large RNAs 
(>200bp) of same origin, indicating that the miRNA machinery as a whole is of vital 
importance for the development and maintenance of dopaminergic neurons (Kim et al., 
2007). All in all, the aforementioned findings suggest that disruption in the miRNA 
machinery might be intrinsically related to the pathogenesis and progression of PD. 
The studies presented above here indicate that miRNAs comprise a very promising 
tool for the discovery of novel pathological aspects of PD and, consequently, for the 
improvement of diagnosis and therapeutic options for this disease. Moreover, the 
possibility of studying not only miRNA expression profiles but also the ones of their direct 
mRNA interactors (by transcriptomic profiling) and the final protein products (by 











1.4. Objectives of this doctoral thesis 
With the advance of biotechnology, large scale high-throughput omics studies 
permit the generation of very detailed datasets with high efficiency and relative low costs. 
That represents a huge advantage to the study of molecular mechanisms and pathways 
involved in the development of complex diseases. Analytical approaches for the 
visualization and integration of multi-omics data allow a deeper look into underlying 
pathophysiological mechanisms, and might permit the exploitation of the finding into novel 
therapeutic strategies. These approaches are especially important in the context of 
neurodegenerative diseases, including PD. Exploring the exact molecular mechanisms 
taking place in the midbrains of PD-affected patients is fundamental for better 
understanding the pathogenesis and progression of the disease. 
Thus, the central aim of this doctoral thesis was to analyze postmortem midbrain 
tissue samples from a cohort of PD patients and controls through a set of multi-omics 
approaches, in order to profile miRNA expression patterns, their target transcripts, the final 
protein products and possible genomic alterations underlying the pathologic phenotypes. 
The main techniques employed here were the following: 
• Gene panel sequencing and Multiplex ligation-dependent probe amplification: 
To verify the presence of classic mutations and other genetic alterations linked 
to PD in a selected set of genes; 
• Small RNA sequencing; 
To profile the miRNA expression patterns in the present midbrain samples; 
• RNA sequencing; 
To obtain the transcriptomic profiles from the present midbrain samples; 
• Mass spectrometry; 
To evaluate the quantifiable proteome in the present midbrain samples; 
Each generated dataset might contain a large number of potential underlying 
mechanisms from PD pathology per se and was analyzed in depth individually. In addition, 





fashion, aiming to depict pathways of deregulation across the omics data that might permit 
the exploration of novel miRNA-based regulatory mechanisms. Overall, our findings are 
likely to reveal molecular networks involved in PD pathogenesis as well as drugable targets 
for the development of novel therapeutic alternatives. 
Finally, to complement our studies in the human tissue, another objective was to 
validate the small RNA / RNA sequencing results from human midbrains in an established 
animal model of PD (the αSyn.A53T transgenic mouse line). By comparing the validation 
results from both sources, our main goal was to verify whether the expression patterns 
observed in PD-affected human brains correlate with the ones found in the animal tissue, 
assessing the validity of the model in terms of miRNA / mRNA expression. 
 




2. Material and Methods 
2.1. Materials 
2.1.1. Human samples 
Case ID Age Sex Duration (y) PMI (h) Neuropathological diagnosis 
PD      
PD029 76 M 7 15 LBDBS 
PD039 82 F 15 12 LBDBS 
PD050 82 F 14 18 LBDBS 
PD074 85 M 9 17 LBDBS 
PD125 74 M 25 20 LBDN 
PD134 74 M 10 21 LBDBS 
PD153 76 F 7 12 LBDN 
PD180 85 F 15 15 LBDN 
PD182 75 M 10 3 LBDN 
PD184 71 M 7 24 LBDE 
PD187 72 M 8 11 LBDN 
PD201 87 M 11 19 LBDN 
PD203 84 F 18 19 LBDN 
PD207 81 M 10 11 LBDN 
PD229 85 F 18 7 LBDN 
PD268 72 M 20 8 LBDN 
PD334 87 M 9 21 LBDN 
PD458 73 M 19 10 LBDBS 
PD666 93 F 15 24 LBDBS 
Controls      
C028 60 F  13 Diffuse hypoxic damage 
C046 65 M  24 Ischemic infarct caudate and capsule 
CO54 66 M  16 n.a. 
C064 63 F  21 n.a. 
CO74 84 F  22 n.a. 




C075 88 M  8.5 n.a. 
C077 84 F  12 n.a. 
PDC023 78 F  23 n.a. 
PDC034 90 M  12 n.a. 
PDC035 89 F  13 Diffuse hypoxic damage 
PDC040 61 F  15 n.a. 
PDC078 91 M  18 n.a. 
PDC087 92 F  24 n.a. 
PDC088 96 F  24 n.a. 
PD549 76 M  25 Age associated changes - normal control 
Table 1: Characterization of the human tissue samples analyzed in this thesis. PMI: post-
mortem intervals; LBD-BS: Lewy body disease, brain stem predominant. LBD-N: Lewy body 





1-Bromo-3-Chloropropane Sigma Aldrich (Germany) 
2-Propanol AppliChem (Germany) 
Ethanol absolute AppliChem (Germany) 
GlycoBlue Coprecipitant ThermoFisher Scientific (USA) 
Phosphate buffered saline (PBS) AppliChem (Germany) 
DNase I (2U/μL)   Life Technologies (USA) 
RNase OUT Life Technologies (USA) 
Nuclease free water Sigma Aldrich (Germany) 
10X DNAse I Incubation buffer Life Technologies (USA) 





Trizol (TRI Reagent) Sigma Aldrich (Germany) 
Table 2: List of Reagents 
 
 
2.1.3. Primers and Kits 
Kit / Primer Producer 
RNA Clean & Concentrator-5 KIT Zymo Research (USA) 
QIAamp DNA Mini Kit Qiagen (Germany) 
miScript II RT Kit Qiagen (Germany) 
miScript SYBR Green PCR Kit Qiagen (Germany) 
Quantitect RT Kit Qiagen (Germany) 
QuantiTect SYBR Green PCR Kit Qiagen (Germany) 
SALSA P051 Parkinson MLPA kit MRC Holland (The Netherlands) 
SALSA P052 Parkinson MLPA kit MRC Holland (The Netherlands) 
TruSeq Small RNA Library Prep Kit Illumina (USA) 
CleanTag Library Preparation for Next-Generation 
Sequencing Kit 
TriLink (USA) 
dsDNA 905 Kit Agilent (USA) 
dsDNA 905 Reagent Kit Agilent (USA) 
TruSeq Stranded Total RNA Illumina (USA) 
RiboMinus Thermo Fisher Scientific (USA) 
Bradford Roti-Nanoquant protein quantification kit Carl Roth (Germany) 




Pierce High pH Reversed-Phase Peptide 
Fractionation Kit 
Thermo Fisher Scientific (USA) 
Hs_RNU6-2_11 miScript Primer Assay Qiagen (Germany) 
Hs_GAPDH_1_SG Quantitect Primer Assay Qiagen (Germany) 
Hs_RIMS1_1_SG Quantitect Primer Assay Qiagen (Germany) 
Hs_DHX57_1_SG QuantiTect Primer Assay Qiagen (Germany) 
Hs_RNF170_1_SG QuantiTect Primer Assay Qiagen (Germany) 
Hs_TMEM178B_1_SG QuantiTect Primer Assay Qiagen (Germany) 
Hs_C7orf73_1_SG QuantiTect Primer Assay Qiagen (Germany) 
Hs_STEAP3_1_SG QuantiTect Primer Assay Qiagen (Germany) 
Hs_MIER2_1_SG QuantiTect Primer Assay Qiagen (Germany) 
Hs_FOXF1_1_SG QuantiTect Primer Assay Qiagen (Germany) 
Hs_SOCS4_1_SG QuantiTect Primer Assay Qiagen (Germany) 
Hs_BRWD1_1_SG QuantiTect Primer Assay Qiagen (Germany) 
Hs_PPTC7_1_SG QuantiTect Primer Assay Qiagen (Germany) 
Hs_ENTPD5_1_SG QuantiTect Primer Assay Qiagen (Germany) 
Mm_Socs4_1_SG QuantiTect Primer Assay Qiagen (Germany) 
Mm_Steap3_1_SG QuantiTect Primer Assay Qiagen (Germany) 
Mm_Mier2_1_SG QuantiTect Primer Assay Qiagen (Germany) 
Mm_Foxf1_1_SG QuantiTect Primer Assay Qiagen (Germany) 
Mm_Pink1_1_SG QuantiTect Primer Assay Qiagen (Germany) 
Mm_Polg_1_SG QuantiTect Primer Assay Qiagen (Germany) 




Mm_Nfkb2_1_SG QuantiTect Primer Assay Qiagen (Germany) 
Mm_Hspa1a_2_SG QuantiTect Primer Qiagen (Germany) 
Mm_Sqstm1_1_SG QuantiTect Primer Assay Qiagen (Germany) 
Mm_Dyrk1a_1_SG QuantiTect Primer Assay Qiagen (Germany) 
Mm_Rims1_1_SG QuantiTect Primer Assay Qiagen (Germany) 
Mm_Galc_1_SG QuantiTect Primer Assay Qiagen (Germany) 
Mm_Nod2_1_SG QuantiTect Primer Assay Qiagen (Germany) 
Mm_Gapdh_3_SG QuantiTect Primer Assay Qiagen (Germany) 
Mm_miR-143_1 miScript Primer Assay Qiagen (Germany) 
Mm_miR-122a_1 miScript Primer Assay Qiagen (Germany) 
Mm_miR-10a_2 miScript Primer Assay Qiagen (Germany) 
Hs_let-7i_1 miScript Primer Assay Qiagen (Germany) 
Hs_miR-26a_2 miScript Primer Assay Qiagen (Germany) 
Hs_miR-218_1 miScript Primer Assay Qiagen (Germany) 
Hs_miR-424_1 miScript Primer Assay Qiagen (Germany) 
Hs_miR-29c_1 miScript Primer Assay Qiagen (Germany) 
Hs_let-7g_2 miScript Primer Assay Qiagen (Germany) 
Hs_miR-20a_1 miScript Primer Assay Qiagen (Germany) 
Hs_miR-145_1 miScript Primer Assay Qiagen (Germany) 
Hs_miR-98_1 miScript Primer Assay Qiagen (Germany) 
Table 3: List of Kits and Primer Assays 
 






7M Urea (Sigma) 10.51 g 
2M Thiourea (Sigma ) 
 
3.8 g 
4% Chaps (Applichem) 
 
1 g 
ASB14 2% (Sigma) 0.5 g 
cOmplete™, Mini, EDTA-free Protease 
Inhibitor (Roche) 
1:25 (v/v %) 
Phos Stop Phosphatase Inhibitor (Roche) 1:20 (v/v %) 
Deionized water q.s. 25 ml 















96 well micro test plates Sarstedt (Germany) 
MicroAmp Optical 96-Well Reaction Plates Applied Biosystems (USA) 
Tecan Spark 10M Plate reader Tecan (Switzerland) 
Mastercylcer nexus X2 Eppendorf (Germany 
Micro-centrifuge 5415R Eppendorf (Germany) 
NanoDrop One Thermo Fisher Scientific (USA) 
Agilent 2100 Bioanalyzer Agilent (USA) 
Fragment Analyzer Agilent (USA) 
Quant Studio 3 q-RT-PCR system Thermo Fisher Scientific (USA) 
QuantiFluor dsDNA System Promega (USA) 
ABI 3130XL or 3500XL capillary seq Applied Biosystems (USA) 
HiSeq 4000 sequencing platform Illumina (USA) 
RNAse-Exitus Plus AppliChem (Germany) 
Eksigent nanoLC425 nanoflow 
chromatography system 
AB Sciex (USA) 
Hybrid triple quadrupole-TOF mass 
spectrometer (TripleTOF 5600+) 
AB Sciex (USA) 
Chrommatography Pre-column (0.18 mm 
ID x 20 mm; symmetry C18, 5 µm) 
Waters (USA) 
Chrommatography RP-C18 column Waters (USA) 
Perfusion syringe Becton Dickinson 
NuPAGE Novex Bis-Tris Minigels Invitrogen (USA) 
Thermomixer Comfort Eppendorf (Germany) 
1.5ml Biosphere Safeseal tubes Sarstedt (Germany) 
Table 5. List of equipment 






CorelDraw Graphics Suite Corel Corporation (Canada) 
GraphPad Prism software version 8.1.2 GraphPad software (USA) 
R software (version 3.5.1) R Core Team, 2017 
Python v.2.7.1 Python Software Foundation 
limma (version 3.36.5) (Ritchie et al., 2015) 
Rank-Rank Hypergeometric Overlap (RRHO) (Plaisier et al., 2010) 
FastQC version 0.11.5 (Andrews et al., 2010) 
QuantStudio Design and Analysis Software v1.5.1 Thermo Fisher Scientific (USA) 
BaseCaller software Thermo Fisher Scientific (USA) 
Analyst TF 1.7.1 software build 1163 AB Sciex (USA) 
Cutadapt (Martin, 2011) 
RNA-STAR version STAR_2.5.2b (Dobin et al., 2013) 
htseq-count script (HTSeq package version 0.9.1) (Anders et al., 2015) 
Bowtie version 1.1.2 (Langmead et al., 2009) 
Coffalyser 
MRC Holland (The 
Netherlands) 
ProteinPilot Software version 5.0 AB Sciex (USA) 
PeakView Software version 2.1 AB Sciex (USA) 
SWATH quantitation microApp version 2.0 AB Sciex (USA) 
Perseus 1.5.6.0 
Computational Systems 
Biochemistry, Max Planck 
Institute, Martinsried Germany 
(Tyanova et al. 2016) 
 
Table 6. List of software used for experiments, data analysis and figure design 














A30P (point mutation) MLPA 
G2019S (point mutation) MLPA 
Parkin Gene panel sequencing 
PINK1 Gene panel sequencing 
DJ-1 Gene panel sequencing 
SNCA Gene panel sequencing 
LRRK2 Gene panel sequencing 
GBA Gene panel sequencing 
VPS35 Gene panel sequencing 
PLA2G6 Gene panel sequencing 
RAB39B Gene panel sequencing 




VPS13C Gene panel sequencing 
TOR1A Gene panel sequencing 
THAP1 Gene panel sequencing 
GCH1 Gene panel sequencing 
GNAL Gene panel sequencing 
SGCE Gene panel sequencing 
KMT2B Gene panel sequencing 
ANO3 Gene panel sequencing 
PRKRA Gene panel sequencing 
RAB12 Gene panel sequencing 
TAF1 (4 variants) Gene panel sequencing 
ADCY5 Gene panel sequencing 
COX20 Gene panel sequencing 
MCOLN1 Gene panel sequencing 
PDGFB Gene panel sequencing 
PDGFRB Gene panel sequencing 
SLC20A2 Gene panel sequencing 
XPR1 Gene panel sequencing 
POLG Gene panel sequencing 
VAC14 Gene panel sequencing 
Table 7. List of genes analyzed in MLPA and gene panel sequencing experiments 
 







2.2.1. Human samples 
2.2.1.1. Human midbrain sample source and ethics statement 
All human midbrain samples were provided by the Parkinson’s UK Brain Bank 
(Imperial College London, London, England). Midbrain tissue blocks (snap frozen) were 
transported and stored under controlled temperature conditions (-80°C). The samples 
were conceded to the Lingor Lab (Department of Neurology of the University Medical 
Center Göttingen, Göttingen, Germany). Ethical approval was given by the Multicenter 
Research Ethics Committee (07/MRE09/72). Table 1 encloses all information about the 
human samples. 
 
2.2.1.2. Midbrain tissue sampling 
For the sake of having the midbrain blocks under controlled temperature 
conditions, the samples were transferred to a cryostat chamber and kept at -20°C for 20 
minutes for temperature balancing.  Each frozen tissue block was punched with a 20-G 
Quincke Spinal Needle (Becton Dickinson, Madrid, Spain), and around 20 mg of were 
collected into RNAse/DNAse free tubes for each sample. Tissue punches were kept at -80°C 
until further use. 
 




Figure 3. Information on human midbrain Samples and tissue processing. (A) Human midbrain 
sample IDs; sample source: UKPD brain bank. (B) Experimental design for RNA isolation and protein 
lysate preparation experiments; extraction of tissue punches was performed with a spinal needle. 




2.2.2. Animal samples 
2.2.2.1. αSyn.A53T mice selection and cohort designing 
Transgenic Prnp-SNCA*A53T mice were provided by the central animal facility (ZTE) 
of the University Medical Center Göttingen. Wild-type / homozygous animals were selected 
upon 10-12 weeks of life and kept in ventilated cages (multiple housing; groups of 
maximum 6 individuals per cage), under a 12-hour dark-light cycle and fed ad libitum. Six 
different cohorts (n = 5 animals/group)  were designed according to genotype and age for 
sacrification. Animals in the ‘early-stage’ cohorts were kept until 100 days of age before 
sacrification. For the ‘intermediate-stage’ and ‘late-stage’ cohorts, animals were kept for 




250 and 400 days of age before scarification, respectively. Animals showing any signals of 
paralysis or weight loss were immediately sacrificed. All experiments were performed in 
accordance with the national German animal protection law under the project 17/2470, 
grant no. 13/1118 approved by the local authorities. 
 
2.2.2.2. Animal euthanasia and tissue processing 
2.2.2.2.1. Cervical dislocation  
Cervical dislocation was employed for mouse euthanasia and performed by a 
trained individual. The animals were restrained by the base of the tail on the wire-bar grid 
of a housing cage. After the animals gripped on the grid, the body was carefully stretched, 
so the base of the skull was completely accessible. Closed scissors were placed on the back 
of the neck/base of the skull and the cervical dislocation was performed with a firm 
horizontal push of the scissors whilst pulling the tail base to the opposite direction. Cervical 
dislocation effectiveness was assessed by palpation of the cervical tissues, and the death 
of the animals was confirmed by checking toe pain reflexes and respiratory arrest. 
 
2.2.2.2.2. Transcranial perfusion 
In order to obtain RNA of good quality for further experiments, fresh, nonfixed 
mouse brain tissue was required. For that sake, after euthanasia, the animals were quickly 
moved to a perfusion table and the abdominal skin was cut open longitudinally. The rib 
cage was cut open in order to expose the heart and a perfusion cannula was inserted into 
the left ventricle. A perfusion syringe (Becton Dickinson, Heidelberg, Germany) filled with 
50 ml of ice-cold PBS was connected to the cannula and the animals were perfused with 
that volume for 3 minutes. After perfusion, the cranium was cut open, the brain was 








2.2.2.2.3. Preparation of midbrain regions from fresh mouse brain 
The mouse brains were microdissected in order to isolate the midbrain region from 
both hemispheres. For that, brains were cut sagittally with a scalpel. After removing the 
olfactory bulb and the cerebellum (by cutting at the cerebellar peduncle), the cortex was 
flipped over until unraveling of the hippocampal structure and both were excised. The 
remaining structures containing the basal ganglia and the pons were further dissected to 
isolate the midbrain region. Freshly prepared midbrains were collected into Nuclease-free 
tubes, snap-frozen with liquid nitrogen and kept at -80°C until RNA isolation experiments. 
 
 
2.2.3. Molecular biology techniques 
2.2.3.1. RNA isolation, DNAse treatment of RNA samples, RNA cleaning and 
concentration 
Total RNA was isolated from human and animal midbrain samples using TRI Reagent 
(Sigma Aldrich, Taufkirchen, Germany). All RNA-related experiments were performed 
under an RNA-workstation fume hood. Shortly, 1 ml of TRI Reagent was added to each 
midbrain sample and incubated for 5 minutes, followed by addition of 100µl of 1-Bromo-
3-Chlor-Propane (Sigma Aldrich, Taufkirchen, Germany). The reaction tubes were mixed by 
inversion for 10 - 15 seconds and incubated at room temperature for 3 minutes. The lysates 
were centrifuged at 12.000 x g for 15 minutes / 4°C, leading to separation of organic and 
aqueous phases. The RNA-containing aqueous phase was transferred to a fresh Nuclease-
free tube. RNA precipitation was performed by adding 500 µl of 2-propanol (AppliChem, 
Darmstadt, Germany) and 2 µl GlycoBlue Co-precipitant (15 mg/ml) (ThermoFisher, 
Waltham, MA, USA), followed by overnight incubation at -20°C. Next, the samples were 
centrifuged at 12.000 x g for 30 minutes / 4°C, the supernatant was discarded and the RNA 
pellets washed three times with 75% ice-cold ethanol (AppliChem, Darmstadt, Germany). 
The pellets were dried for 5 minutes under the fume hood, reconstituted with 15-20 µl of 
Nuclease-free water (Sigma Aldrich, Taufkirchen, Germany) and RNA samples incubated at 
55°C for 2 minutes in a thermoshaker in order to completely dissolve the RNA. 




After the RNA isolation, a DNAse treatment was performed in order to remove any 
remaining DNA from the samples. For that, 5μl of 10X DNAse I Incubation buffer (Life 
Technologies, Carlsbad, CA, United States) were added to each sample, followed by the 
addition of 5μl DNase I (2U/μL) and 0.5μl - RNase OUT (40U/μl). Samples were made up to 
a volume of 50 µl by the addition of Nuclease-free water, followed by incubation at 37°C 
for 20 minutes. Finally, the RNA samples were cleaned and concentrated with the RNA 
Clean & Concentrator-5 KIT (Zymo Research, Irvine, CA, USA), following the manufacturer’s 
instructions. 
 
2.2.3.2. DNA isolation and sample processing 
DNA isolation from human midbrain samples was performed with the QIAamp DNA 
Mini Kit following the manufacturer’s instructions. Midbrain DNA samples were freshly 
prepared and directly shipped to the Laboratory of Translational Neurogenetics (Institute 
of Neurogenetics, University of Lübeck) for MLPA and gene panel sequencing experiments.  
 
2.2.3.3. Determination of nucleic acid concentration and purity 
Directly after RNA / DNA isolation, nucleic acid concentration and purity were 
measured in the NanoDrop One spectrophotometer (ThermoFisher, Waltham, MA, USA). 
Spectrophotometric quantification in the NanoDrop system required 1 μl of each sample. 
For RNA samples used in RNA sequencing experiments, RNA integrity was assessed with 
the Agilent 6000 Nano Chip in the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). 
 
2.2.3.4. Reverse transcription 
For quantitative real-time PCR experiments (q-RT-PCR), complementary DNA 
(cDNA) synthesis was performed. For miRNA q-RT-PCR validation experiments, 500 ng of 
RNA from each sample were reverse transcribed using the miScript II RT Kit (Qiagen, Hilden, 
Germany) with the HiSpec buffer (designed for the reverse transcription of mature 
miRNAs). For transcriptomics validation experiments, 1 µg RNA / sample was reversed 




transcribed using the QuantiTect Reverse Transcription Kit (Qiagen, Hilden, Germany). All 
steps were performed on ice. A master-mix was prepared for each RT reaction, as follows: 
Component Volume/reaction 
5x miScript HiSpec Buffer 
10x miScript Nucleics Mix 
miScript Reverse Transcriptase Mix 
Template RNA (volume for 500ng) 






Total Volume 10 μl 
Table 8. Components for Reverse Transcript reactions 
Following the addition of the master mix to the samples, the reaction tubes were 
incubated for 60 minutes at 37 °C in the Mastercycler nexus X2 PCR thermocycler 
(Eppendorf, Hamburg, Germany), followed by incubation at 95°C for 5 minutes to inactivate 
the reverse transcriptase. cDNA samples were diluted 1:3 in nuclease-free water and stored 
at -20 °C until q-RT-PCR experiments. 
 
2.2.3.5. Quantitative Real-Time Polymerase Chain Reaction (q-RT-PCR) 
To determine expression levels of selected miRNAs and mRNAs in human and 
animal midbrain samples, q-RT-PCR reactions were conducted in the QuantStudio 3 system 
(ThermoFisher, Waltham, MA, USA). For miRNA q-RT-PCR experiments, the miScript SYBR 
Green PCR Kit (Qiagen, Hilden, Germany) was used, and miRNA expression was normalized 
to the endogenous control RNU 6.  For the validation of transcriptomics experiments, the 
QuantiTect SYBR Green PCR Kit (Qiagen, Hilden, Germany) was employed, using GAPDH as 
a housekeeping control. MicroAmp Optical 96-Well Reaction Plates (Applied Biosystems, 
Foster City, CA, USA) were prepared at room temperature and the reaction plates were 
tightly sealed with a heat-sealing adhesive film before placement inside the cycler. Reaction 
volumes were calculated as described in the tables below. 
 
 





Table 9. miScript q-RT-PCR Reactions Master mix (for miRNA validation experiments)  
 
Table 10. QuantiTect q-RT-PCR Reactions Master mix (for mRNA validation experiments) 
  
The cycling conditions are described in the table below. A melt curve analysis was 
set for every q-RT-PCR run. 
Table 11. qPCR cycling settings 
Component Volume/reaction 
2x QuantiTect SYBR Green PCR Master Mix 
10x miScript Universal Primer 








Total volume 20 µl 
Component Volume/reaction 
2x QuantiTect SYBR Green PCR Master Mix 







Total volume 25 µl 
Step Time Temperature 











Cycle number 40 cycles 




 The relative expression levels of miRNA and mRNA species were calculated by the 
ΔΔCt method (delta-delta-Ct). Ct values for each sample were compared to the average of 
ΔCt of the respective control group. 
 
2.2.3.6. Multiplex Ligation-dependent Probe Amplification (MLPA) 
MLPA experiments were performed in order to detect abnormalities in copy 
numbers (e.g. deletions, duplications, triplications) of specific PD-related genes. For the 
MLPA analyses, SALSA P051 and P052 Parkinson MLPA kits (MRC Holland, Amsterdam, The 
Netherlands) - a set of standard commercial probes - were employed. These kits cover 
exons that include Parkin, PINK1, and DJ-1 and selected mutations in LRRK2 and SNCA 
genes. Further analyzed exons are listed in table 7. DNA samples were prepared (as 
described in 2.2.3.2) and shipped to the lab of Prof. Christine Klein / Dr. Katja Lohmann 
(Universität zu Lübeck), were the experiments were perfomed. MLPA experiments were 
conducted according to the manufacturer's protocol. PCR amplification products were 
visualized on capillary sequencing machines (either ABI 3130XL or 3500XL) (Applied 
Biosystems, Foster City, CA, USA) using the coffalyser software (MRC Holland, Amsterdam, 
The Netherlands). 
 
2.2.3.7. Gene Panel sequencing 
For Gene Panel analysis, similar to the MLPA experiments, DNA samples were 
prepared (as described in section 2.2.3.2) and shipped to the lab of Prof. Christine Klein / 
Dr. Katja Lohmann (Universität zu Lübeck) for the DNA sequencing. After preparation of the 
panels, the samples were sequenced on a next-generation sequencing platform with a 
collaboration partner (Centogene AG, Rostock, Germany). 29 genes previously linked to PD 
or dystonia (DYT) phenotypes were analyzed. The mean sequencing depth was 600x. 
Variants were filtered according to quality scores (cut-offs: quality score >200; coverage 
>10, allele fraction >20%), further filtered for the number of times that they appeared in 
public databases (cut-off: <0.01 in public databases and the in-house database) and finally 
for protein-changing variants in PD genes. Candidate variants were confirmed by Sanger 
sequencing. All genes included in the gene panel are disclosed in table 7. 





2.2.3.8. RNA sequencing experiments 
2.2.3.8.1. Small RNA sequencing library preparation 
Small RNA sequencing experiments were performed in the Transcriptome and 
Genome Analysis Laboratory (TAL) of the University Medical Center Göttingen. Small RNA 
libraries were prepared using the TruSeq Small RNA Library Prep Kit (Illumina, San Diego, 
CA, USA) with minor modifications. 600 ng total RNA were used as starting material for 
library preparation. In order to prevent the formation of adapter dimers (by 5΄ and 3΄ self-
ligation) and consequent amplification of these dimers, the CleanTag Library Preparation 
for Next-Generation Sequencing Kit (TriLink, San Diego, CA, USA) was employed.  
 
2.2.3.8.2. Small RNA sequencing library quality assessment 
Small RNA libraries quality and integrity were assessed in the Fragment Analyzer 
platform (Agilent, Santa Clara, CA, USA). Therefore, the standard sensitivity RNA Analysis 
Kit was used. All samples selected for sequencing exhibited a comparable RNA integrity 
number (7-8). For accurate quantitation of small RNA libraries, a library pool was quantified 
with the QuantiFluor dsDNA System (Promega, Madison, WI, USA). Finally, the size of the 
small RNA libraries was determined using the dsDNA 905 Reagent Kit (Agilent, Santa Clara, 
CA, USA). Small RNA sequencing was performed on the Illumina HiSeq 4000 platform 
(Illumina, San Diego, CA, USA), generating 50 bp single-end reads (10-20 Million reads/ 
sample).  
 
2.2.3.8.3. RNA sequencing library preparation 
Likewise small RNA sequencing experiments, transcriptomics were performed in the 
Transcriptome and Genome Analysis Laboratory (TAL) of the University Medical Center 
Göttingen. The same RNA source was used for both small RNA and RNA sequencing 
experiments. RNA libraries were prepared using a modified version of the TruSeq Stranded 
Total RNA protocol (Illumina, San Diego, CA, USA), a strand-specific, massive-parallel cDNA 
sequencing protocol. 200 ng of total RNA were used as a start material. A ribosomal RNA 
(rRNA) depletion protocol (RiboMinus™, ThermoFisher, Waltham, MA, USA) was 




performed in order to maintain rRNA content under 5% in the samples. Shortly, this 
technology utilizes specific locked nucleic acid (LNA) bind rRNA and subsequently to 
streptavidin-coated magnetic beads to remove those species from the samples. Next, an 
adaptor ligation step is performed, followed by PCR amplification of the reads. A reduced 
number of PCR cycles was employed in order to avoid PCR duplication artifacts, as well as 
primer dimers in the final libraries.  
 
2.2.3.8.4. RNA sequencing library quality assessment 
A Fragment Analyzer (Agilent, Santa Clara, CA, USA) was used for assessment of RNA 
quality and integrity. RNA integrity numbers from all samples selected for sequencing 
ranged from 7-8. For accurate quantitation of the libraries, the QuantiFluor dsDNA System 
(Promega, Madison, WI, USA) was employed. cDNA library sizes were determined with the 
dsDNA 905 Kit (Agilent, Santa Clara, CA, USA). Finally, the libraries were pooled and 
sequenced on an Illumina HiSeq 4000 (Illumina, San Diego, CA, USA) generating 50 bp 
single-end reads (30-40 Million reads/sample).  
 
2.2.3.8.5. Raw sequencing reads and sequencing quality check 
After RNA sequencing runs, sequence images were transformed to BCL files with 
the BaseCaller software. Thereafter, the files were demultiplexed to fastq files with 
bcl2fastq v2.17.1.14. Both software were provided by Illumina (Illumina, San Diego, CA, 
USA).  Quality check of the reads fastq files was done with FastQC version 0.11.5  (Andrews 
et al., 2010) 
 
2.2.3.9 Proteomics experiments 
2.2.3.9.1 Lysate preparation 
For proteomics experiments, human midbrain tissue lysis was performed in freshly 
prepared Urea/Thiourea/Chaps lysis buffer. The detailed composition of the lysis buffer is 
depicted in table 4. Samples were homogenized with plastic stabs and lysates were 
spinned-down in order to remove bubbles produced by the manual homogenization. For a 




fine homogenization of the lysates, the samples were sonicated twice for 15-second 
intervals at an amplitude of 40%. Sonication was performed on ice. A new centrifugation 
step was performed to remove the produced bubbles. 
 
2.2.3.9.2 Protein quantification and sampling 
 Protein quantification was performed with the modified-Bradford Roti-Nanoquant 
protein quantification kit (Carl-Roth, Karlsruhe, Germany), following the manufacturer’s 
instructions. The prepared colorimetric reactions were read in the TECAN Spark 10M Plate 
reader. A final amount of 50 µg protein was aliquoted for further proteomics experiments. 
 
2.2.3.9.3 Mass spectrometry runs 
For mass spectrometry (MS) experiments, previously prepared protein aliquots 
(50µg protein/sample) were loaded into a 4-12% NuPAGE Novex Bis-Tris Minigels 
(Invitrogen, Carlsbad, CA, USA). Samples were run for 1.5 cm by electrophoresis and stained 
with Coomassie Brilliant Blue. The bands were cut out, diced and undergo reduction with 
the use of dithiothreitol, alkylation with iodoacetamide. Next, proteins were digested with 
trypsin overnight. Tryptic peptides were extracted from the gel and the solution was dried 
in a Speedvac (Atanassov and Urlaub, 2013). For the generation of peptide libraries, equal 
aliquots from each sample were pooled to a total of 80 µg and further separated into eight 
fractions using a reversed-phase spin column (Pierce High pH Reversed-Phase Peptide 
Fractionation Kit) (ThermoFisher, Waltham, MA, USA). Spike-ins from a synthetic peptide 
standard were added to the samples and used for retention time alignment (iRT Standard, 
Schlieren, Switzerland). Protein digests were analyzed on the Eksigent nanoLC425 nanoflow 
chromatography system (AB Sciex, Framingham, MA, USA), hyphenated to a hybrid triple 
quadrupole-TOF mass spectrometer (TripleTOF 5600+) equipped with a Nanospray III ion 
source (Ionspray Voltage 2400 V, Interface Heater Temperature 150°C, Sheath Gas Setting 
12) and controlled by Analyst TF 1.7.1 software build 1163 (AB Sciex, Framingham, MA, 
USA). Briefly, peptides were dissolved in a loading buffer (composed of 2% acetonitrile and 
0.1% formic acid in water) to a concentration of 0.3 µg/µl. For each analysis, 1.5 µg of 
digested protein was enriched on a pre-column of dimensions 0.18 mm ID x 20 mm and 




symmetry C18, 5 µm (Waters, Milford, MA, USA). Next, separation was performed on an 
analytical RP-C18 column of dimensions 0.075 mm ID x 250 mm, HSS T3, 1.8 µm (Waters, 
Milford, MA, USA) using a 90 min linear gradient of 5-35 % acetonitrile / 0.1% formic acid 
(v:v) at 300 nl min-1. 
 
2.2.3.9.4 Mass spectrometry analysis 
Qualitative liquid chromatography/tandem mass spectrometry (LC-MS/MS) analysis 
was performed using a Top25 data-dependent acquisition method. For that, an MS survey 
scan of m/z 350–1250 accumulated for 350 ms at a resolution of 30,000 full width at half 
maximum (FWHM) was performed. MS/MS scans of m/z 180–1600 were accumulated for 
100 ms at a resolution of 17,500 FWHM and a precursor isolation width of 0.7 FWHM, 
resulting in a total cycle time of 2.9 s. Precursors above a threshold of 125 cps for MS 
intensity and with charge states of 2+ / 3+ / 4+ were selected for MS/MS. Dynamic exclusion 
time was set to 30 s. An MS/MS activation was achieved by CID using nitrogen as a collision 
gas. The manufacturer’s default rolling collision energy settings were employed. Three 
technical replicates per reversed-phase fraction were analyzed to construct a spectral 
library. For quantitative sequential window acquisition of all theoretical fragment ion 
spectra (SWATH) analysis, MS/MS data were acquired using 65 variable size windows 
across the 400-1,050 m/z range. Fragments were produced using rolling collision energy 
settings for charge state 2+, and fragments acquired over an m/z range of 350–1400 for 40 
ms per segment. With the inclusion of a 100 ms survey scan, the overall cycle time was of 
2.75s. Either two or three replicate injections were acquired for each biological sample 
(Gillet et al., 2012; Losensky et al., 2017; Zhang et al., 2015).  
 
2.2.3.10 Bioinformatics analyses 
MLPA and gene panel sequencing data processing was done in collaboration with 
the lab of Prof. Christine Klein / Dr. Katja Lohmann (Universität zu Lübeck). RNA sequencing 
quality control and data processing were performed with the assistance of Dr. Gaurav Jain 
(Lab of Prof. André Fischer, DZNE Göttingen) using in-house developed pipelines. 
Processing of Proteomics data was performed in collaboration with the lab of Prof. Henning 




Urlaub / Dr. Christof Lenz (UMG Göttingen). Proteomics differential expression (DE) 
analyses were done with the assistance of the Department of Medical Statistics (UMG 
Göttingen). 
 
2.2.3.10.1 Small RNA sequencing data processing and mapping 
After small RNA sequencing, the data was processed with a customized in-house 
pipeline (Jain, 2018). After fastq file quality control check with FastQC, the 3' adapters were 
trimmed and reads with the minimum length of 16 nucleotides were filtered out with the 
Cutadapt pipeline (Martin, 2011). The reads are then mapped to the reference genome for 
miRNAs and piRNAs known sequences, followed to the reference genome made from other 
small noncoding RNAs. The remaining unmapped reads were mapped to the human 
genome.  Bowtie version 1.1.2 (Langmead et al., 2009) was employed for all mapping steps, 
and no mismatches were allowed for reads ≤ 32 b. For reads between 33 b and 50 b, one 
mismatch was tolerated.  
 
2.2.3.10.2 RNA sequencing analyses data processing and mapping 
Likewise, the small RNA sequencing data processing, the RNA sequencing data were 
processed with a customized in-house pipeline (Jain, 2018). Adapter trimming and 
demultiplexing were performed alongside base calling. Quality control of raw sequencing 
reads was performed using FastQC. RNA reads were mapped to the human transcriptome 
using RNA-STAR version STAR_2.5.2b (Dobin et al., 2013) for all mapping steps. The reads 
were mapped in the non-splice-junction-aware mode and no mismatches for the reads <19 
b were allowed. For reads between 20 b and 39 b, one mismatch was allowed, and for reads 
between 40 b and 59 b, two mismatches were tolerated. Besides the parameters depicted 
here, all other parameters were default in RNA-STAR. Aligned reads overlapping exons (for 
each gene) was counted with the intersection-non-empty mode of the htseq-count script 
(HTSeq package version 0.9.1) (Anders et al., 2015).  
 




2.2.3.10.3 Mass spectrometry data processing and mapping 
Protein identification was achieved using ProteinPilot Software version 5.0 build 
4769 (AB Sciex, Framingham, MA, USA) at thorough settings. A total of 407,752 MS/MS 
spectra from the combined qualitative analyses were searched against the UniProtKB 
human reference proteome (revision 04/2018, 93.609 entries) augmented with a set of 52 
known common laboratory contaminants. Spectral library generation and SWATH peak 
extraction were achieved in PeakView Software version 2.1 build 11041 (AB Sciex, 
Framingham, MA, USA) using the SWATH quantitation microApp (version 2.0 build 2003). 
Following retention time correction by the iRT standard, peak areas were extracted using 
information from the MS/MS library at a False Discovery Rate (FDR) of 1% (Lambert et al., 
2013). Finally, the resulting peak areas were summed to peptide area values and next to 
protein area values.  
 
2.2.3.10.4 Differential expression and sample correlation analyses for small RNA 
sequencing/transcriptomics 
In order to identify the differentially expressed (DE) small RNAs and genes (from 
both small RNA sequencing and transcriptomics experiments), linear shifts associated with 
different batches of shipped samples were removed using the removeBatchEffect function 
from the limma package (Ritchie et al., 2015). Thereafter, unwanted sources of variation 
(RUVs) were identified and corrected by the RUVSeq script (v. 1.8.0) (Risso et al., 2014). 
Finally, the DESeq2 pipeline (v. 1.14.1) using a variance-stabilizing transformation was 
employed to perform the DE analysis for small RNA / transcriptomics datasets (Anders and 
Huber, 2010; Love et al., 2014). Heatmaps and volcano plots were generated either with a 
custom python script (python v.2.7.1 and Matplotlib 1.5.1) or with the web-enabled 
Heatmapper tool (Babicki et al., 2016). For the for small RNA sequencing dataset, the cut-
offs for significantly DE small RNAs were basemean ≥ 20, log2foldchange <> 0.20 and FDR ≤ 
0.1 were adopted for further analyses. Because of the substantially greater number of 
mapped reads for the transcriptomics dataset, more stringent cut-offs were adopted for 
further analyses, as follows: basemean ≥ 20, log2foldchange <> 0.20 and FDR ≤ 0.05. 
Pairwise sample correlation analyses for small RNA sequencing results were performed 
using Bayesian Hierarchical Clustering (Heller and Ghahramani, 2005; Savage et al., 2019) 




2.2.3.10.5 Differential expression analyses for proteomics 
For the proteomics data, DE analyses were conducted in the R software (version 
3.5.1) (R Core Team, 2017)  using the limma (version 3.36.5) (Ritchie et al., 2015) accounting 
for technical replication (Smyth et al., 2005). Normalized protein quantitation data have 
been log2 transformed prior to the analyses. Heatmaps and volcano plots were generated 




2.2.3.10.6 Putative signature for miRNA data 
Using the miRNA expression data, a putative signature iteration was performed in 
order to identify potential informative features for differentiation between PD and Control 
groups in the dataset. Briefly, Measure of Relevance (MoR) was performed in the first 
iteration. With the MoR analysis, the features were evaluated according to parameters that 
include biological difference, distribution overlap and dispersion parameters of the 
samples. Thereafter, a machine learning variable ranking was performed in order to filter 
out low ranking miRNAs from the previous iteration. MoR values are then assigned to the 
features and filtered (as described in  Yassouridis et al., 2012). A reliability investigation 
iteration (RiA) (Denk et al., 2015) was performed to test the output features in randomized 
stratified samplings of the dataset (n = 500), and class weights were adopted in order to 
minimize false negatives. The final features were selected from the overlapping outputs 
from both analyses. 
 
 
2.2.3.10.7 Stepwise candidate selection from integrative results (within datasets) 
Figure 4 illustrates the exact steps performed for the multi-omics integration, from 
the complete datasets (DE results from each technique) to the selection and validation of 
overlapping candidates across the datasets. Further details on each method are depicted 
below. 




2.2.3.10.7.1 Rank-Rank Hypergeometric Overlap 
The integration of the datasets was performed stepwise, first from the small RNA 
to the transcriptomics datasets, and then from the transcriptomics to the proteomics 
dataset. For the integration of the first two datasets, the available pipeline entitled Rank-
Rank Hypergeometric Overlap (RRHO) was applied (Plaisier et al., 2010). Briefly, this 
bioinformatical pipeline assigns an enrichment score to the components of two different 
datasets based on DE data (p-value / log2FoldChange values and directionality). Then, the 
method overlaps the two ranked lists using features that include rank-based gene set 
enrichment analysis and hypergeometric statistics. For the miRNAs / transcripts 
integration, only the discordant overlap was considered (i.e. down-regulated miRNAs from 
small RNA sequencing dataset paired with the respective up-regulated target (mRNA) from 
the transcriptomics dataset, and vice-versa). In contrast, for mRNAs / proteins integration, 
only concordant overlaps were considered (i.e. only up-regulated transcripts from the 
transcriptomics dataset paired with the respective up-regulated protein product from the 
proteomics dataset - and vice-versa). The full datasets were used as an input for the 
pipeline and the output results were generated in the form of excel sheets. 
 
 
2.2.3.10.7.2 Cross-checking lists 
After the stepwise integration using the RRHO pipeline, the output lists were 
extracted and filtered in terms of significance. For that, the specific cut-offs defined for 
each dataset during DE analyses. A manual stepwise cross-check of DE lists was performed. 
Similar to the RRHO pipeline integration, only valid interactions were considered (i.e. 
discordant expression between miRNA and mRNAs, concordant expression between 
mRNAs and proteins), narrowing down the RRHO output results to a final list of candidates 
from the stepwise dataset integration. These final lists were considered for the selection of 
validation candidates both in human and animal q-RT-PCR validation experiments. 
 
 




2.2.3.10.7.3 Selection of validation targets from RNA sequencing experiments 
After obtaining the final list of miRNA and mRNA candidates from the RRHO and list 
cross-check methods, the probability of interaction between miRNA-mRNA pairs was 
assessed in the TargetScan 7.2 database (Agarwal et al., 2015). Among its functionalities, 
this database allows the ranking of the targeting predictions by their probability of 
conserved targeting (Pct scores) (Friedman et al., 2008). For the selection of miRNA / mRNA 
candidates for q-RT-PCR validation experiments, only interactions with Pct values  ≥  0.7 
were considered (aiming for pairs with the highest probability of interaction among the 
ones identified in the integrative approaches). 





Figure 4. (A) Stepwise integration of the human multi-omics datasets and candidate selection for 
q-RT-PCR validations (both for miRNA and transcriptomics in human and mouse midbrain tissue). 
DE results from each technique considered as the starting input for integrative approaches. 
 
 




2.2.3.10.8 Functional annotation and target prediction tools 
As described in the previous section, target prediction of miRNA species was done 
with the TargetScanHuman 7.2 database (Agarwal et al., 2015). This database predicts 
miRNA targeting according to nucleotide sequence and miRNA seed region. Experimentally 
validated targets were retrieved from the miRTarBase database (Chou et al., 2018). 
Functional annotation of transcripts / miRNA predicted targets, as well as enrichment 
analyses (Gene Ontology and KEGG Pathway analyses),  were performed both with the 
DAVID 6.8 platform (Huang et al., 2009a, 2009b) and WEBGESTALT (Liao et al., 2019). Data 
mining for experimentally validated miRNA target lists was performed with the miRWalk 
3.0 database (Sticht et al., 2018). 
 
2.2.3.10.9 Statistical analyses 
Besides the aforementioned bioinformatical pipelines for DE analyses, statistical 
analyses were conducted with the GraphPad Prism software version 8.1.2 (GraphPad, San 
Diego, CA, USA). q-RT-PCR relative expression data were tested for normality with both 
D'Agostino & Pearson omnibus normality test and Shapiro-Wilk tests. For the human 
relative expression values, group comparisons were tested with the non-parametric Mann-
Whitney-U test.  For the animal validation experiments, group comparisons were 
performed with mixed-effects ANOVA followed by the Bonferroni post-hoc test. Statistical 
tests and cohort numbers are always indicated in the respective figure legends. Data are 
given as mean ± standard error of the mean (SEM). Differences were considered significant 







3.1 Assessment of genetic alterations in PD patients by MLPA and gene panel 
sequencing 
In order to explore the genetic background of PD patients selected for this study, 
genomic DNA from midbrains of the PD patient cohort was extracted and both  Multiplex 
Ligation-dependent Probe Amplification (MLPA) and gene panel sequencing were 
performed (Figure 5A). The presence of classic mutations and further genetic alterations 
previously linked to PD pathophysiology were assessed for selected genes.  
First, deletions, duplications and triplications in specific PD-related genes were 
verified using MLPA runs. This is a multiplex PCR-based method that allows the detection 
of abnormal copy numbers for given genes. PD-specific MLPA probemix kits – the SALSA 
P051 and P052 – were applied. The screening revealed no changes in copy numbers of the 
examined genes. MLPA results revealed no alterations in copy numbers of genes that 
included Parkin, PINK1, DJ-1, LRRK2 and SNCA genes (Figure 5B). 
A gene panel comprising 29 genes previously linked to PD or DYT phenotypes was 
applied for targeted next-generation sequencing analysis of the PD patient cohort. No 
major alterations were found in the patients by gene panel sequencing. One patient 
(PD666) presented a variation of uncertain significance (VUS) for the POLG gene (single 
nucleotide variant, NM_001126131.1:c.2542G>A). Studies linked the presence of this 
variant to alteration in PD predisposition and progression in the carriers (Gui et al., 2015b; 
Luoma et al., 2007). None of the other patients presented mutations in the analyzed genes 
according to the gene panel sequencing (Figure 5C). The findings indicate that the cohort 
is composed of idiopathic PD cases, excluding a major genetic influence to the PD cases 
analyzed in this work. In spite of phenotypic overlaps between familial and idiopathic cases 
for PD, the different pathogenic/cellular events underlying autosomal forms of PD have not 
been focused in the course of this study (Cookson et al., 2005; Papapetropoulos et al., 2007; 











Figure 5. Gene panel and MLPA experiments overview. (A) Experimental design; after quality 
check, DNA samples were processed in MLPA / Gene panel sequencing experiments (B) Exemplary 
MLPA results for a PD patient showing no alteration (deletion, duplications or triplications) for the 
explored genes. Likewise, no alterations were found in the PD patient cohort. (C) Gene panel 
experiments reveal a single nucleotide variant (length: 1 bp) for the POLG gene in one of the PD 












3.2 Small RNA sequencing overview and small RNA profiles in PD / control midbrains 
In order to evaluate the small RNA content and profile the miRNA expression 
patterns in the present cohorts, total RNA was isolated from the midbrain of controls and 
PD patients. Subsequently, RNA quality control and small RNA sequencing was performed 
on the Illumina HiSeq 4000 platform (Figure 6A). To this, small RNA libraries were prepared 
from total RNA from each midbrain sample. Libraries from all patients had a satisfactory 
number of uniquely mapped reads (>50.000 reads/library) and were further used for 
downstream analyses of sequencing results (Figure 6B).  
Figure 6. Small RNA sequencing overview. (A) Experimental design; after quality check, small RNA 
libraries were prepared from total RNA from each midbrain sample. Sequencing performed in the 





small RNA library size for samples from individual subjects (dark purple: PD patients; light purple: 
controls). Values correspond to uniquely mapped reads. (C) Pie charts showing average ratios of 
the different small RNA species detected in the small RNA libraries as a readout for quality of the 
sequencing technique; miRNAs represent the vast majority of mapped small non-coding RNAs in 
both conditions  (dark purple: PD patients; light purple: controls). (D) Top 15 expressed miRNAs in 
all samples; bar at the far right represents the sum of remaining miRNAs found in the samples. The 
central plot represents the distribution of all miRNA species detected in the sequencing. 
 
All bioinformatical analyses were performed in collaboration with the Lab of Prof. 
André Fischer using in-house modified pipelines. The vast majority of mapped small RNA 
sequencing counts were composed by miRNAs in both PD and control conditions (90.39 % 
and 92.61 % of all mapped counts for different small RNA species, respectively) (Figure 6C). 
Amongst the top 15 miRNA with the highest average expression in all subjects, at least 4 
miRNAs (miR-181a-5p, miR-127-3p, miR-99b-5p, miR-9-5p) have been previously reported 
to be brain / CNS specific (Figure 6D) (Hinske et al., 2014). The normalized expression for 
miRNA species was considered for the following downstream and DE analyses. 
 
3.3 Differential expression analyses of small RNA sequencing results reveal regulated 
and potential signature miRNAs for PD 
DE analyses conducted with small RNA sequencing results showed regulation in the 
expression of a number of miRNAs in PD patient samples in comparison to controls (Figure 
7A). A custom cut-off for a minimum number of reads was defined in order to exclude very 
lowly expressed miRNAs (min. number of reads per condition = 20). Under the default 
DESeq2 pipeline conditions for DE analyses (log2FC ± 1; FDR < 0.05), 21 miRNAs were found 
regulated. For exploratory handling of the miRNA expression data, less stringent cut-offs 
were applied for the fold-change in expression and FDR corrections (log2FC ± 0.1; FDR < 
0.1) and considered for subsequent pathway enrichment analyses with miRNA targets. 
Under those parameters, significant differences in the expression of 27 miRNAs were 






In order to have an overview about the expression levels of regulated small RNA 
species in different disease states (PD / controls), a heatmap was created using the full 
output of the DESeq2 differential analyses (Figure 7C). The heatmap shows variable 
expression patterns for the different species within conditions with a rather high inter-
individual variability in both PD and control groups.  
Figure 7. Differential expression results for small RNA sequencing experiments. (A) Volcano plot 





the log2FoldChange in the expression of transcripts. The volcano plot  was generated under default 
DESeq2 pipeline cut-offs (Significant species indicated in colors; red = FDR < 0.05; green = FDR < 
0.05 and log2FC ± 1). A custom cut-off for a minimum number of reads was defined (min. nr. Reads 
per condition = 20), and a less stringent cut-off for the log2FC and FDR correction was employed 
for subsequent exploratory pathway analyses(log2FC ± 0.1; FDR < 0.1). With that, 27 miRNAs were 
found DE and were considered for further analyses.  (B) Plot showing the Measure of Relevance 
(MoR) used for the identification of miRNA putative signatures for the discrimination of disease 
state in the analyzed cohorts. The dotted orange line represents the MoR value cut-off. miRNAs 
above the cut-off are considered informative. (C) Heatmap for DE transcripts; comparison between 
PD and control samples. The color key indicates expression levels of DE small RNAs per patient. The 
dendrogram on the left indicates hierarchical clustering based on expression level. 
  
Parallel to the DE analyses, the small RNA sequencing dataset was used for the 
development of an iterative feature analysis based on miRNA expression. Aiming to identify 
candidates for the discrimination between PD and control samples, Measure of Relevance 
(MoR) analysis was performed, followed by a machine learning variable ranking for the 
selection of the informative features. All the mapped miRNA reads were used as an input 
to the MoR pipeline. Additionally, a reliability analysis (RiA) was performed with the 
discovered candidates (as depicted in section 2.1.3.10.6). With these analyses, a set of 10 
miRNAs were identified as potential putative signatures for the discrimination of disease 
states with the analyzed samples (Figure 7B). Four of those were also significant in the 
aforementioned DE analyses and are marked with stars in the putative signature plots 
(namely, miR-29a-3p,  miR-223-3p, miR-29c-3p, let-7g-5p). 
 
3.4 Sample correlation analyses 
In order to check the overall inter-individual differences in small RNA expression of 
PD patients, a Bayesian Hierarchical Clustering was performed. These analyses required 
normalized mapped counts without any transformation as an input.  Therefore, the batch 
correction algorithms used to treat the data prior to DE analyses were not applied here. In 
order to exclude a bias related to the different sequencing runs, the expression data from 





clustering (Figure 8). The results show that the PD patients show high heterogeneity in 
regard to small RNA expression, concordant to what was observed in the Heatmap for DE 
analyses. Different clusters and sub-clusters for patients with similar small RNA expression 
are revealed with hierarchical clustering analyses. Relevant clinical data are also depicted 
for each analyzed patient. Parameters that include age, gender, disease duration and post-
mortem intervals (PMI) are shown in color codes and indicate also a big variability in the 
distribution of clinical features. Although, there is no obvious correlation from those with 
the different clusters for small RNA expression. 
Figure 8. Bayesian Hierarchical Clustering analysis of PD patients for small RNA sequencing data. 
(A) Triangular heatmap showing unbiased clustering analysis. Samples with similar expression are 
located next to each other in clusters (dendrogram links in blue and red). PD patients of a single 
batch from sequencing runs considered for the analyses (n = 13). Clinical parameters corresponding 
to each PD patient showed in rectangles at the bottom of the triangular heatmap. PMI: Post-
mortem intervals; LBDBS: Lewy body disease (alpha-synucleinopathy), brain-stem predominant; 
LBDE: LBDE: Lewy body disease, early-neocortical; LBDN: LBDN Lewy body disease, neocortical. 






3.5 Literature screening links differentially expressed miRNAs to important biological 
processes both in health and disease 
A thorough literature search was performed using the miRNAs found significantly 
deregulated in the present study. The PubMed database (NCBI-NIH) was screened for 
publications that included the regulated miRNAs until the year 2019.  The various key-terms 
employed in the literature mining were related to important biological and cellular 
processes that included, for example, neuronal development, function, plasticity and 
survival, as well as neurodegenerative processes and disorders, inflammatory and immune 
response, among others. The key-terms were sub-categorized as shown in Figure 9. 
Figure 9. Literature compilation; key terms related to the differentially expressed miRNAs found 
in the small RNA sequencing experiments. (A) Up-regulated miRNAs in PD on the left-hand side 
(list in orange), Down-regulated miRNAs in the right-hand side (list in blue). Color key indicates the 






The diagram shows that the candidates have been already linked to several neuron-
related processes (both in health and disease), as well as in cancer studies. The screening 
revealed that almost half of the DE miRNAs found here were previously linked to PD or 
dopaminergic neuronal function, the category with the highest number of matches. Several 
of them were also linked to processes that include neuronal differentiation and 
development, aging and neurodegeneration, as well as neuronal apoptosis and survival. 
Several of the up-regulated miRNAs were also linked to inflammatory and immune 
response, processes which have been broadly associated to neurodegenerative diseases, 
including PD (Barcia et al., 2003; Hunot and Hirsch, 2003; Tiwari and Pal, 2017). 
 
3.6 Functional annotation with targets of differentially expressed miRNAs identify 
important enriched pathways in the context of PD 
In order to further explore the functional role of the DE miRNAs in the context of 
PD, a computational miRNA-target prediction was performed, followed by functional 
enrichment analysis in the Web-based gene set analysis toolkit (WebGestalt). Gene 
ontology (GO) for biological processes (BP) and cellular components were annotated using 
the targets of up- and down-regulated miRNAs separately (Figure 10). Moreover, only 
experimentally validated targets were retrieved for the functional annotation, aiming to 
have the highest level of evidence enriched in the gene ontology terms. For targets of up-
regulated miRNAs, results show that almost one-third of the enriched gene ontology terms 
are related to neuronal function, follow by a high ratio of processes related to 
nucleus/chromosome and cell division. Cytoskeleton related terms account to one-fifth of 
the enriched gene ontology terms.  Figure 10B show the 15 most significant gene ontology 
terms for biological processes for targets of miRNAs found up-regulated in PD patients. 
Enriched terms include cell development and proliferation-related processes, as well as 





Figure 10. Functional enrichment analysis for targets of differentially expressed miRNAs. (A and 
C) Proportion of enriched gene ontology processes to different cellular component merged 
categories. (B) Gene ontology term enrichment for targets of significantly up-regulated miRNAs. (D) 
Gene ontology term enrichment for targets of significantly down-regulated miRNAs. X-axes 
represent -log2 of FDR corrected values for the functional enrichment. Experimentally validated 





On the other hand, validated targets for miRNAs found down-regulated in PD 
showed no enrichment for neuronal-related processes. Nucleus/chromosome- and cell 
division- related terms followed by cytoskeleton- and cell growth-related terms account to 
50 % off all enriched gene ontology terms (26 % and 24 %, respectively) (Figure 10C). 
Vesicular- and membrane-related terms account to 19 % of the GO results, while 
mitochondria-related terms comprise 7% of the enrichment. In more detail, several of the 
most highly ranked significant GO terms are related to gene expression, transcription and 
other RNA-related processes. Furthermore, gene ontology terms related to response to 
stress, apoptosis and protein phosphorylation, as well as regulation of phosphorus and 
phosphate metabolic processes are among the top 15 most significant enriched GO-BP 
terms (Figure 10D). Functional enrichment analyses for regulated miRNA targets indicate 
that these candidates might be involved in important biological processes that range from 
cell proliferation and maintenance to gene expression, stress and apoptotic related 
processes. The previous evidence for the involvement of those miRNAs in PD 
pathophysiological events is further explored in the integration of the various datasets 
object of this work.  
3.7 RNA sequencing overview and transcriptomic raw data processing 
RNA sequencing experiments were performed in order to assess the transcriptomic 
profiles of the present midbrain cohorts. For that, RNA aliquotes coming from the same 
sample source used for the small RNA sequencing experiments were used. RNA sequencing 
experiments were performed on the Illumina HiSeq 400 platform. In a similar way, as 
previously described for the small RNA sequencing, RNA libraries were prepared directly 
from the sourced total RNA from each midbrain sample for both PD and control cohorts 
(Figure 11A). Quality control performed with the sequencing output files (fastQC) denoted 
satisfactory quality information from the RNA sequencing for all analyzed samples (Figure 
11B). Read counts coming from individual patient/control libraries were then mapped and 
relative expression values for the whole transcriptome were assigned to the sequencing 
results of each subject. Normalization and removal of unwanted variances (RUV) were 
performed with the output results (Figure 11C) previous to downstream functional 
enrichment analyses. Sequencing read counts were mapped and assigned to the reference 






Figure 11. RNA sequencing overview. (A) Experimental design; after quality check, RNA libraries 
were prepared from total RNA from each midbrain sample. Sequencing performed in the Illumina 
HiSeq 400 platform followed by bioinformatical analysis. (B) Exemplary plot showing quality 
information from the sequencing of an RNA sample. Quality (Phred) score is represented in the Y-
axis. Quality scores reflect the Illumina estimate for the probability of a particular base to be 
identified incorrectly (cite). In the example, all read nucleotides lie on the ‘good quality’ region of 
the plot (same for the rest of the samples)  (C) Relative log expression (RLE) plots showing the 
expression levels of the whole transcriptome for all samples; plots represent variances after 







3.8 Transcriptomic differential expression analyses point towards dopaminergic 
depletion and massive inflammation/immune response in midbrains of PD subjects 
DE analysis was performed with the RNA sequencing results in order to explore gene 
expression in midbrains of PD patients when compared to controls. Following the mapping, 
the complete output from the RNA sequencing was used for the DESeq2 pipeline. Only 
protein-coding genes were considered for downstream analyses. A cut-off value for a 
minimum number of reads was adopted in order to filter out very lowly expressed genes 
from the differential analysis (min. nr. reads = 50). Furthermore, custom cut-offs values for 
the fold change in expression and false-discovery rate were applied during data analysis  
(log2FC ± 0.2; FDR < 0.05). Under these conditions, a total of 1452 transcripts were found 
significantly deregulated in PD in comparison to controls. Similar to what was observed in 
the small RNA sequencing results, the majority of transcripts – 975 of them - were found 
up-regulated in PD, whereas 477 transcripts appear down-regulated in that condition.  
A volcano plot correlating significance to the log2FoldChange in gene expression is 
presented in Figure 12A, showing DE transcripts in colors. These plots were generated 
under DESeq2 default settings for FDR and log2FoldChange and considered the full 
transcriptomic expression data before the aforementioned filtering. Highlighted transcripts 
were extracted from pathway enrichment analyses depicted below. A gene expression 
heatmap was generated for the transcriptomic significant results, in order to have an 
overview of the overall expression in different subjects and disease states. (Figure 12B). 
Despite inter-individual variabilities in the expression profiles, the general transcriptomic 
profile seems to be concordant to the disease state, showing a more obvious pattern in 










Figure 12. Differential expression results for RNA sequencing experiments and pathway analyses. 
(A) Volcano plot showing DE miRNAs in midbrain samples from the different cohorts. Significant 
species indicated both in colors (volcano plots created under DESeq2 default settings: red = FDR < 
0.05; green = FDR < 0.05 and log2FC ± 1). For the sub-sequential pathway and integrative analyses, 
only coding genes were considered. Custom cut-offs for a minimum of 50 reads per condition and 
minimum log2FC of ± 0.2 were employed, leading to a final number of DE 1452 transcripts (PD vs. 
controls comparison). Enrichment analyses (performed with the DAVID Database) revealed altered 
biological processes related to inflammatory response and several pathways related to the immune 
response in PD midbrains (highlighted for up-regulated transcripts); down-regulated transcripts 
show enrichment to terms that include translational machinery and dopamine-related processes. 
(B) Heatmap for DE transcripts; comparison between PD and control samples. Color key indicates 
expression levels of DE transcripts per patient. (C) Gene Ontology (GO) – Biological Processes term 
enrichment status for down-regulated transcripts in PD. (D). Gene Ontology (GO) – Biological 
Processes term enrichment status for up-regulated transcripts in PD. (E) KEGG PATHWAY 
enrichment status for down-regulated transcripts in PD. (F) KEGG PATHWAY enrichment status for 
up-regulated transcripts in PD. Bars represent p-values (log2 transformed) for the respective terms. 
Pathway analyses conducted in DAVID Functional Annotation Tool 6.8. 
 
Functional enrichment analyses were conducted aiming to explore 
pathophysiological events that might underline the results for the transcriptomic profiling 
of PD and control midbrains. Up- and down-regulated transcripts in PD from the DE analysis 
were considered separately (Figures 12D/F). The functional annotation with down-
regulated transcripts revealed enrichment for several important gene ontology terms, 
including translational machinery, synaptic transmission and protein localization. Pathways 
related to dopamine signaling/metabolism and locomotory behavior, hallmark processes 
in PD pathology (Dauer and Przedborski, 2003b; Langston et al., 1983; Ungerstedt et al., 
1974), were among the enriched terms. KEGG pathway analyses retrieved alterations in 
metabolic pathways, ribosome processes, dopamine-related pathways and 
neurodegenerative diseases including PD itself (as the third most significant pathway 
enriched for down-regulated transcripts). The annotated down-regulated transcripts 
included tyrosine hydroxylase (TH), Dopa decarboxylase (DDC), dopamine transporters 





For up-regulated transcripts, functional enrichment analyses revealed altered gene 
ontology terms (GO-BP) related to inflammatory response and several pathways related to 
the immune response in PD midbrains (Figure 12C). Moreover, KEGG pathway analyses 
with up-regulated genes indicate a massive activation of the immune system and 
inflammation-related pathways, being the majority of significantly enriched pathways 
related to those processes. Inflammation and activation of the adaptative immune system 
have been implicated in the context of PD  progression (Fiszer et al., 2009; McGeer et al., 
1988b; Ouchi et al., 2005; Tristão et al., 2016). Pathways related to apoptosis, NFKB-, 
MAPK- and RAB1-signalling were also enriched for transcripts up-regulated in PD (Figure 
12E). The presence of different infectious diseases enriched in the analyses might be 
related to the high number of immune system-related transcripts found up-regulated in PD 
(as highlighted in the volcano plot in Figure 12A – highlighted transcripts in red selected 
from the intersection between inflammatory/immune response and apoptosis enriched 
pathways. Highlighted transcripts, namely, IKBKB; BAX; RELA; PIK3CD;TRAF2; TNFRSF10B; 
CASP4; NFKB2; CIITA; C3; CXCR4).  
In summary, findings in this dataset indicate that multiple pathways contribute to 
PD mechanisms, rendering an integrative analysis for the present multi-omics data very 
promising for the exploration of novel miRNA-based regulatory mechanisms. 
 
3.9 Differences in protein content in PD and control midbrain are portrayed by 
proteomics analysis 
Mass spectrometry experiments were performed in order to profile the proteomic 
changes in PD and control midbrains samples. Protein lysates were prepared from midbrain 
tissue punches directly adjacent to the ones used for small and RNA sequencing 
experiments. The protein content was run into electrophoresis gels and subsequentially 
digested for preparation of peptide libraries. The analysis method of Sequential window 
acquisition of all theoretical fragment ion spectra (SWATH) was employed for the mass 
spectrometry experiments. (Figure 13A). A spectral library was used to extract peptide-
specific peak areas. These areas are combined with protein quantitation values, which are 
then identified and mapped to the human reference proteome (Figure 13B). After 





to an FDR of 1%. DE analyses were conducted with the log2 transformed data of protein 
quantitation and the significance level was set to alpha = 5% for all the differential statistical 
analyses for the proteomics dataset. DE results revealed 127 significantly regulated 
proteins in PD in comparison to controls. As seen in the two previous datasets, the majority 
of the DE proteins were found up-regulated in PD (87 proteins), whereas 40 of them were 
down-regulated in the same condition. These results are presented in a volcano plot 
correlating the significance to the log2FoldChange in expression (Figure 13C).  
Figure 13. Proteomics overview and differential expression analyses. (A) Experimental design; 
proteins extracted from midbrain tissue undergone electrophoresis and trypsinization, 





performed, followed by data analysis. (B) Exemplary workflow for SWATH-MS experiments. The left 
panel shows the global MS/MS product ion maps of all precursors. A spectral library is used to 
extract peptide-specific peak areas, which are finally combined for protein quantitation. (Schematic 
representation of SWATH-MS Workflow kindly provided by Dr. C. Lenz - UMG Göttingen).  (C) 
Volcano plot showing DE proteins in midbrain samples. Significant species indicated in colors; 
down-regulated (in blue) and up-regulated (in red) in PD in comparison to controls (straight line in 
red: cut-off for p < 0.05). 87 proteins were significantly up-regulated in PD, whereas 40 proteins 
were found down-regulated in that condition. (D) Heatmap for DE transcripts; comparison between 
PD and control samples. Color key indicates expression levels of DE transcripts per patient. 
Next, the results from the DE analyses were used for designing a heatmap for the 
protein expression (Figure 13D). In order to exclude technical biases linked to the SWATH-
MS runs, only the biggest sample batch processed in the mass spectrometry experiments 
was considered for designing the heatmap (similarly to what was done sample correlation 
analyses for the small RNA expression). For the proteomics experiments, this batch 
accounted for 13 PD samples and 13 controls. The profiles for protein expression present 
certain concordance to the disease state. Nevertheless, inter-individual differences appear 
similar to the other omics datasets presented previously. 
 
3.10 Functional enrichment of proteomics data reveals regulation in PD-related 
pathways 
Similar to what was done for the previous datasets, DE results from the proteomic 
profiling were analyzed in terms of functional annotation using the Web-based gene set 
analysis toolkit (WebGestalt). The enrichment results showed gene ontology terms related 
to the regulation of protein folding as the most enriched category. Defects of protein 
folding have been extensively linked to neurodegenerative diseases, including PD (Dauer 
and Przedborski, 2003b; Ebrahimi-Fakhari et al., 2013; Ross and Pickart, 2004; Ryu et al., 
2002; Selkoe, 2003, 2004). Another important term appearing in the enrichment analyses 
for the regulated proteins in PD midbrains is the Oxidation-reduction processes, a category 
that is also broadly linked to PD pathophysiology (Fahn and Cohen, 1992; Jenner, 2003; 






Figure 14. Functional enrichment results for proteomics expression data. (A) Enrichment ratio plot 
correlating the log2 of enrichment values of significant gene ontology terms for biological processes 
(assigned by the WebGestalt tool); names of the significantly enriched terms are highlighted and 
also shown in the ranked bar plot on the upper-right corner. (B) Directed Acyclic Graph (DAG) 






Table 12. List of proteins annotated to each GO category in the functional enrichment 
Enriched GO Terms 
Annotated / total 
nr. of proteins in 
GO term 
Proteins annotated in each GO term set 
Negative regulation of 
protein folding 
2 / 5 SNRNP70,  ST13 
Drug metabolic process 17 / 760 
ATP5ME, CBR1, CD47, FAH, GPD1, MAOB, NDUFB3, 
NDUFB8, NDUFS2, OGDH, PFKFB2, PGM2L1, PRDX1, 
PRDX6, PRPS2, PSAT1,TH 
Oxidation-reduction 
process 
18 / 968 
CBR1, CISD1, COX6C, ECHDC1, GPD1, MAOB, MECR, 
NDUFB3, NDUFB8, NDUFS2, OGDH, DIA4, PGM2L1, 
PHYHD1, PRDX1, PRDX6, SELENBP1, TH 
Immune effector 
process 
20 / 1141 
ACTR10, ARPC1A, ATP8A1, C1QC, CAMK4, CD47, CHI3L1, 
CREG1, CRK, FABP5, HTRA1, KRT1, LAMP2, NCKIPSD, 
PA2G4, PADI2, PRDX1, PRDX6, RAB18, SERPINA3 
Secretion by cell 24 / 1472 
ACTR10, ATP8A1, CD200, CD47, CHI3L1, CREG1, ERP29, 
FABP5, KRT1, LAMP2, LGALS3BP, MAOB, PA2G4, PADI2, 
PDIA4, PFKFB2, PRDX6, RAB18, RAB8A, SERPINA3, 
SLC1A3, SLC25A6, SPTBN1, SYP 
Organophosphosphate 
metabolic process 
18 / 1148 
ATP5ME, CAPN2, CPNE6, ENPP6, FABP5, GPD1, MPI 
NDUFB3, NDUFB8, NDUFS2, OGDH, PFKFB2, PGM2L1, 
PLCD3, PRDX6 PRPS2, TKT, VAC14 
Vesicle mediated 
transport 
27 / 1942 
ACTR10, AP3D1, ARPC1A, ATP8A1, CD47, CHI3L1, CPNE6, 
CREG1, CRK, CTNNB1, FABP5, KRT1, LAMP2, LGALS3BP, 
MAP2K2, MSN, NCKIPSD, OSBPL1A, PA2G4, PADI2, 




22 / 1776 
ATP5ME, CAPN2, CTNNB1, DARS, EIF4A1, FABP5, GPD1, 
HNRNPR, MPI, MTPN, OGDH, PA2G4, PFKFB2, PGM2L1, 





In concordance to the transcriptomics results, the immune effector process term 
was also enriched for the DE proteins in PD. Further enriched processes include drug 
metabolic process, secretion by cell, organophosphate metabolic process, vesicle-mediated 
transport and organonitrogen compound biosynthesis. These functional enrichment results 
are presented in a Directed Acyclic Graph (DAG) for a compact biological processes tree 
(Figure 14B). In summary, the enrichment results for the proteomics results outlined 
important mechanisms related to PD pathology in the analyzed samples and added another 
level of evidence further explored in integrative approaches. 
 
3.11 Step-wise integration of multi-omics dataset for pathway identification 
In order to identify DE pathways across the different omics data sets (miRNA targets 
or coding products), the multi-omics results were integrated using both a bioinformatical 
tool (the Rank-Rank Hypergeometric Overlap, RRHO)(Plaisier et al., 2010) and a manual 
cross-checking method for the differential results lists derived from each technique (see 
Figure 4 and section 2.1.3.10.7). 
 
3.11.1 Integration of Small RNA and Transcriptomic datasets 
A computational target prediction for the DE miRNAs in PD and control midbrains 
was performed using the TargetScan 7.2 database (Agarwal et al., 2015). This database 
allows the prediction of miRNA targeting according to nucleotide sequence and miRNA 
seed region. Furthermore, with TargetScan 7.2 it is also possible to retrieve the probability 
of conserved targeting scores (Pct scores) for miRNA target prediction (Friedman et al., 
2008). For the integration of the present datasets, the list of predicted targets was retrieved 
for miRNAs found up- and down-regulated in PD midbrains in comparison to controls. 
Next, the discordant overlap between the two lists was assessed by RRHO and 
manual cross-check of differential results for small / total RNA sequencing data (Figure 
15A). Significantly regulated candidates from both datasets were considered for these 
analyses. These methods allowed the extraction of the valid miRNA-mRNA interactions 





expression in the samples - i.e. up-regulated miRNA paired with the respective down-
regulated targets mRNA, and vice-versa). 
The RRHO algorithm required the full sequencing DE results from both sequencing 
techniques as an input, retrieving a total of 163 DE transcripts presenting valid interactions 
with regulated miRNAs. On the other hand, the manual approach used the stricter custom 
cut-off values applied for the DE and other downstream analyses from each sequencing 
dataset. With that, miRNAs and transcripts with a very low number of reads and/or very 
slight fold change in expression were filtered out from start (as described in sections 3.4 
and 3.9). Those settings resulted in a much smaller outcome for valid interactions: 23 
miRNA targets (DE transcripts) were found cross-checking the differential results.  
Remarkably, these two integrative methods showed a great overlap in their 
outcomes, with 22 out of the 23 DE transcripts found with the manual method being 
present in the RRHO integrative results. This overlap was considered for further steps, and 
a final list of 22 transcripts (namely, DHX57; RNF170; REEP1; TMEM178B; BRWD1; ACADSB; 
CNTN1; SIAE; NHLRC3; ENTPD5; CGNL1; C7orf73; SOCS4; ZNF202; ATPB3; KCNK6; STEAP3; 
CYB561D1; MIER2; FOXF1; RIMS1; KLHL6 and PPTC7) and 9 miRNAs (namely, let-7i-5p; miR-
26a-5p; miR-2018-5p; miR-424-5p; miR-29c-3p; let-7g-5p; miR-20a-5p; miR-145-5p and 
miR-98-5p) that potentially regulate those transcripts were extracted (Figure 15B). The 
exact miRNA-mRNA pairs is depicted in Figure 15C. 
In order to narrow down the list of miRNA-mRNA pairs and select candidates for a 
q-RT-PCR validation of the sequencing results, only interactions with Pct values  ≥  0.7 were 
considered. With that, pairs with the highest probability of interaction among the 
candidates identified in the integrative approaches were extracted. 12 out of the 22 
identified transcripts -  and all of the 9 miRNAs potentially regulating them - were selected 








Figure 15. Integrative approaches for miRNA and mRNA expression data and selection of targets 
for validation. (A) Integration was done by two different methods; manual cross-check method 
between DE lists / RRHO (Rank-Rank Hypergeometrical Overlap) bioinformatical approach (Plaisier 
et al., 2010). Only valid interaction between miRNA-mRNA pairs were considered. (B) Overlap 
between the two methods shows that 22 mRNA are potentially regulated by 9 miRs. (C) Selection 
of miRNA/mRNA candidates for validation; using a cut-off for Pct values (Pct≥ 0.7) (Friedman, et al., 






3.11.2 Integration of Transcriptomic and Proteomic datasets 
Similar to what was done in the previous section, the overlapping results from the 
transcriptomic and the proteomic datasets were explored. In here, inversely to what was 
done for the miRNA/transcriptome integration, the concordant overlap between coding 
transcripts and their respective protein products were of interest (i.e. up-regulated 
transcript paired with the respective up-regulated protein product). Factors like protein 
kinetics, synthesis and degradation rates were out of the scope of this study and therefore 
not considered for these analyses.Here, we applied the manual cross-check method for the 
integration (Figure 16A), due to the very different nature and coverage of the proteomics 
results in comparison to the RNA sequencing results. Additionally, the much smaller range 
of DE proteins (127) was also favorable for such an approach. 
The total number of uniquely identified proteins – 2,257 – was more than 20 times 
smaller than the number of mapped transcripts (46,500). Consequently, several of the 
transcripts found DE by RNA sequencing did not have their respective protein product 
identified in the proteomics results, and the opposite was at times also true. The first step 
for the integration of these two datasets was to look for transcripts and respective protein 
products which were found differentially regulated in both datasets (Figure 16B). From the 
1422 DE transcripts found in RNA sequencing experiments, 30 of them also had the 
respective protein product significantly deregulated determined by proteomics 
experiments. When considering only valid mRNA-Protein pairs (concordant expression 
patterns), the integrative overview of the two datasets delineates a final list of 7 up-
regulated candidates (namely, ATP6V1E1; C9ORF47; CD47; ACOT7; RPL35; SEC23A and 
RPN1) and 6 down-regulated candidates (TH; DBT; CD200; RAB18; NIPSNAP3A and UBE2L3) 
(Figure 16C) (regulation given PD vs controls). These candidates are currently being 
validated by Western Blotting and the results will not figure in the scope of this thesis. The 
presence of a very important marker for dopamine metabolism (tyrosine hydroxylase [TH]) 
among the down-regulated candidates in both datasets adds more evidence to the results 





Figure 16. Integrative approaches for mRNA and protein expression data (A) Overlap between 
proteomics and transcriptomics datasets reveal that from 127 significant DE proteins, 30 of them 
also present the respective DE coding transcript in RNA sequencing experiments. (B) Integration 
was done by two different methods; manual cross-check method between DE lists. Only valid 
interactions between mRNA-Protein pairs considered. (C) Final list of proteins presenting significant 
DE in both datasets and expressed in the same fashion (in orange: up-regulated 






3.12 Validation of small RNA sequencing results in human midbrain tissue by q-RT-PCR 
The 9 miRNA candidates selected after the integrative approaches of the small RNA 
and RNA sequencing results (section 3.11.1) were validated by q-RT-PCR. Since there was a 
substantial amount of time between the RNA sequencing experiments from the validation 
of the selected candidates, new tissue punches were collected from frozen midbrain 
samples from each individual. A fresh RNA isolation was conducted right before the start 
of the validation experiments, followed by the production of cDNA samples by reverse 
transcription. q-RT-PCR validation experiments were conducted in the QuantStudio 3 
platform (Figure 17A). 
For selected miRNAs found down-regulated in PD by RNA sequencing experiments, 
relative expression levels from q-RT-PCR results show that all tested miRNAs presented 
significant differences in expression concordant to the small RNA sequencing results (Figure 
17B). On the other hand, for selected miRNAs found up-regulated in PD by RNA sequencing 
experiments, q-RT-PCR results showed a significant difference in expression levels of two 
miRNAs (let-7i and miR-29c). Interestingly, both miRNAs presented the opposite direction 
for the regulation.  
Overall, four out of the nine selected miRNAs were successfully validated by q-RT-
PCR, presenting concordant expression to what was found in DE analyses with the small 







Figure 17. Validation of small RNA sequencing results (selected miRNAs) by q-RT-PCR. (A) Relative 
expression levels of selected miRNAs found up-regulated in PD patients. (B) Relative expression 
levels of selected miRNAs found down-regulated in PD patients. Error bars show standard error of 





3.13 Validation of transcriptomics results in human midbrain tissue by q-RT-PCR 
Parallel to the miRNA validation in the midbrain samples, the 12 mRNA transcripts 
selected in the integrative approaches (section 3.11.1) were also validated by q-RT-PCR. 
Fresh RNA was aliquoted from the same sample source used for the miRNA q-RT-PCR 
validation, and cDNA samples were prepared using the Qiagen Quantitect reverse 
transcription kit. The PCR reactions were conducted in the QuantStudio 3 platform (Figure 
16A) 
Seven from the selected transcripts presented a significant up-regulation in PD in 
RNA sequencing experiments. According to the relative expression results, four out of the 
seven candidates were also found significantly up-regulated in q-RT-PCR experiments, 
concordant to the findings from the transcriptomics. Another two mRNAs presented 
apparent up-regulation in PD samples, but relative expression results were not significant 
(Figure 18B). 
Opposite to the aforementioned findings, from the transcripts presenting down-
regulation in RNA sequencing results, there were no significant differences in relative 
expression levels in q-RT-PCR experiments. Despite the non-significant results, all 
transcripts presented, on average, lower expression levels in comparison to controls. 
Possibly, the limited cohort size is influencing the statistical power of the experiments 
presented here (Figure 18C). 
In summary, a limited number of candidates found DE in RNA sequencing 
experiments presented a concordant significant regulation by q-RT-PCR, both for selected 
miRNAs (4/9 candidates validated) and mRNA transcripts (4/12). Technical and sensitivity 
differences in the two methods could account for these divergent findings. Nevertheless, 
the patterns of the relative expression levels determined by q-RT-PCR were similar to the 






Figure 18. Validation of RNA sequencing results (selected mRNAs) by q-RT-PCR. (A) Relative 
expression levels of selected mRNAs found up-regulated in PD patients. (B) Relative expression 
levels of selected mRNAs found down-regulated in PD patients. Error bars show standard error of 





3.14 Comparison of human RNA sequencing results with data from a PD mouse model  
Another objective of this thesis was to evaluate whether the alterations observed 
in the human tissue could be reproduced in a common mouse model for PD. Therefore, 
experiments with the transgenic alpha-synuclein[A53T] mouse model (αSyn.A53T) were 
designed to explore the findings from the small RNA and RNA sequencing experiments in 
the midbrain tissue of αSyn.A53T mice. These mice express the human form of the αSyn 
protein with the A53T point mutation. This mutation can lead to severe and progressive 
motor phenotypes in the carrier animals, with an average onset at 8 months of age (Giasson 
et al., 2002) Briefly, transgenic αSyn.A53T mice were bred and both, wild type and 
homozygous animals, were selected shortly after birth for the experimental cohorts. Six 
cohorts were designed according to the genotype and the anticipated age at sacrifice (n = 
5 animals per group). The animals were kept under controlled conditions. Early-stage 
animals were sacrificed at 100 days of age, intermediate-stage mice were sacrificed at 250 
days of age and late-stage at 400 days of age (or whenever any signs of pathology were 
shown). After sacrification, animal brains were micro-dissected and snap-frozen. Midbrain 
tissue from the selected animals was processed in the exact same way as done for human 
q-RT-PCR validation studies  (Figure 19A). 
 
3.14.1 Validation of PD-deregulated miRNAs in αSyn.A53T midbrains 
Similar to what was done with the human midbrain tissue, total RNA was isolated 
from mouse midbrain and cDNA samples were prepared by reverse transcription reactions. 
The q-RT-PCR validation experiments were conducted in parallel to the ones performed 
with the human midbrain tissue (Figure 19B). The relative results were tested for 
significance between mutated and control genotypes within each age group. The miRNAs 
presenting significant differences in the validations studies in humans were further 
selected for the validation in mice (Figure 19C). Furthermore, a miRNA target prediction 
was performed in TargetScan 7.2 (Agarwal et al., 2015) in order to find any further miRNAs 
potentially regulating the mRNA transcripts selected for validation (selected targets shown 
in the section below). From the several retrieved miRNAs, three miRNAs were also found 
to be regulated in human small RNA sequencing results and were also selected for 





Figure 19. Mouse model - experimental setup and validation of selected miRNA targets. (A) 
Experimental setup for the mouse validation study. αSyn.A53T transgenic mice were bred from 





Animals were sacrificed according to age (early-stage = 100 days; intermediate stage = 250 days; 
late-stage = 400 days; total number of groups = 6). Late-stage animals were sacrificed either at end 
point or when symptoms of paralysis / pronounced weight loss started to appear. After sacrifice, 
mouse brains were microdissected into different brain regions and snap-frozen for further use. RNA 
was isolated from midbrain samples from animals (n = 5 animals per group). Groups were tested 
for significance between mutated and wild-type genotypes within the different age groups. (B) 
Experimental setup for miRNA q-RT-PCR validation of targets selected from the human midbrain 
small RNA sequencing results. (C ; D) Relative expression levels of selected miRNAs in midbrains of 
transgenic animals. Panel C shows relative expression levels of selected miRNAs found deregulated 
in PD patients. Panel D shows relative expression levels of newly selected (see Figure 4 / section 
3.14.1 for the selection of targets). Error bars show standard error of the mean. Data analyzed by 
mixed-effects ANOVA followed by Bonferroni post-hoc test. * p < 0.05, ** p < 0.01, *** p < 0.001 
  
The validation results indicate no differences between the genotypes at the early-
stage groups, an evidence for a possible age-related alterations in miRNA expression. The 
relative expression levels of all miRNAs show a trend to reduced expression in both wild 
type and homozygous genotypes in the intermediate stage groups compared to their 
expression levels at the early-stage group. The relative expression of miRNAs at late-stage 
groups seems to be more variable, although significant changes were only found for one 
miRNA species there (miR-98). 
For two candidates (mir-98 and miR-20a), alterations in late-stage and 
intermediate-stage groups, respectively, were concordant to the results presented in the 
human midbrain tissue validation. The expression levels for both miRNAs were significantly 
down-regulated in homozygous groups in comparison to the respective controls at the 
given time points. Another miRNA (miR-145) presented significantly up-regulated levels in 
homozygous animals in comparison to wild-type groups at the intermediate stage - an 
opposite finding to the results from the human tissue validation (Figure 19C). miR-122a 
presented a trend for up-regulation in mutated animals (Figure 19D). Outlier values for 






3.14.2 Validation of PD deregulated mRNAs in αSyn.A53T midbrains 
Similar to the miRNA candidate selection described in the previous chapter, mRNA 
species successfully validated in human tissue by q-RT-PCR were now selected for 
validation the αSyn.A53T mouse model (Figure 20B). Furthermore, in order to have a 
deeper look into the possible correlation of pathological features presented by the 
αSyn.A53T mice in relation to PD pathology in humans, further transcripts were selected 
for validation by q-RT-PCR. First, genes that were previously described to be involved in PD 
pathogenesis and pathophysiology in humans were retrieved from a comprehensive review 
of PD and the cellular processes involved the pathogenesis of the disease (Kalia and Lang, 
2015). Next, a screening of the results of the largest genomic-wide association study in PD 
(which involved the analysis of 7.8 million single nucleotide polymorphism [SNPs] in dozens 
of thousands of PD cases and more than one million control cases) was performed (Nalls et 
al., 2018). For both strategies, the cut-off criterion was that candidates had to be 
significantly regulated in the RNA sequencing results from the human midbrain study. With 
the aforementioned setting, 9 further transcripts were selected for validation by q-RT-PCR 
in the αSyn.A53T mouse tissue (Figure 20C). 
Similar to the miRNA validation in the previous section, the statistical evaluation of 
the results focused on the differences between the different genotypes in each stage. The 
results showed that in general, most of the evaluated genes present changes between 
genotype groups either at an earlier stage (already at 100 days of age) or at an intermediate 
time points (250 days of age). Significant differences in the relative expression levels of 
SOCS4 (intermediate stage) fitted the findings from the transcriptomics validation in the 
human tissue, while the significant findings for MIER2 (both in early and in intermediate 
stages) were opposed to the ones found in humans. Interestingly, for the further selected 
targets, all the relative expression changes were observed as an up-regulation in the 
homozygous animals: DYRK1a (both in early and in intermediate stages), GALC (early stage), 
HSPA1 (intermediate stage), PINK1 (both in early and in intermediate stages), POLG1 (early 
stage), RIMS1 (intermediate stage) and SQSTM1 (early stage). No differences were found 
in the late stage groups, suggesting again that relative expression might be influenced by 





Figure 20. Experimental setup and validation of selected mRNA targets in midbrains of control 





from the human midbrain small RNA sequencing results. (B) Relative expression levels of selected 
mRNAs (previously validated in human midbrain tissue) in midbrains of transgenic animals. (C) 
Relative expression levels of further selected targets for q-RT-PCR validation with the αSyn.A53T 
mouse midbrain tissue. Error bars show standard error of the mean. Data analyzed by mixed-effects 








To this date, the exact molecular mechanisms underlying the pathogenesis and 
progression of PD are not completely understood. In addition, the diagnosis of PD mainly 
relies on clinical criteria related to the motor dysfunction presented by the patients. Since 
the symptoms only start to appear at advanced stages of the nigrostriatal degeneration 
characteristic in PD, there is a strong limitation for the promotion of therapeutic strategies 
that might be able to change the course of the disease. Allied to that, the limited 
regenerative capabilities of cells in the central nervous system complicate the development 
of restorative treatment options.  
Profiling the expression of molecular elements such as miRNAs, transcripts and 
proteins in brains affected by PD might reveal a series of pathological events taking place 
both at cellular and systemic levels in the course of the disease. Ultimately, these 
approaches might provide valuable insights into PD progression and facilitate the 
development of novel disease-modifying therapies. The present doctoral thesis aimed to 
analyze midbrain tissue samples from a cohort of PD patients and controls in a multi-omics 
set of experiments, looking into the genetic background of the selected subjects, as well as 
characterizing the expression patterns of miRNAs, transcripts and proteins on those 
samples. By approaching the multi-omics techniques both individually and in an integrative 
way, we aimed to identify patterns of deregulation potentially containing novel 
pathomechanisms related to PD, with special focus to miRNA-based regulatory processes 
underlying the disease. Finally, an animal model of PD was evaluated in respect to the 
changes observed in the human tissue, in order to assess the similarity of the pathological 
mechanisms occurring in both systems. 
 
4.1 No major genetic alterations are found in the PD patient cohort 
In order to evaluate the genetic background of the present PD-patient cohort and 
explore possible alterations influencing the course of the disease, targeted gene evaluation 
was performed with both gene panel sequencing and MLPA techniques for pre-selected 
known PD-associated genes. With the latter technique, the presence of deletions, 





results revealed no alterations for the present cohort, indicating the absence of copy 
number abnormalities for the genes examined. 
Gene panel sequencing experiments identified a VUS (variation of uncertain 
significance) for the POLG gene in one out of the nineteen PD patients (variant 
NM_001126131.1:c.2542G>A in patient PD666). A couple of studies linked the presence of 
POLG variants to PD predisposition in Finnish and Chinese populations, based on alterations 
in mitochondrial DNA copy number in the variant carriers (Gui et al., 2015b; Luoma et al., 
2007). Nevertheless, no mechanistic evidence for this specific VUS in the pathophysiology 
of PD is found in the literature. All in all, the MLPA and gene panel sequencing experiments 
showed that no significant genetic alterations are present in the analyzed patients for the 
classical PD-related genes. These results indicate that the present PD cohort seems to be 
homogeneously composed of idiopathic cases. However, it is important to highlight that 
the techniques employed here are targeted and, therefore, restricted in terms of screening 
for alterations in the whole genome. Thus, the presence of causative mutations in genes 
not contained in the pre-selected panel cannot be excluded. Although studying genetic 
cases might reveal a number of important mechanisms in the context of PD pathology, the 
main focus of this study was to investigate the molecular events taking place in idiopathic 
PD midbrains, which account for the vast majority of cases.  Therefore, for the subsequent 
analyses presented here, we did not focus on any particular pathomechanisms related to 
the known autosomal forms of PD. 
 
4.2 Small RNA sequencing results reveals differentially expressed miRNAs in PD 
including candidates with potential discriminative power 
Small RNA sequencing experiments were employed in order to evaluate the small 
RNA content and profile miRNA expression patterns in the present midbrain samples. The 
sequencing results revealed that the vast majority of mapped small RNA reads accounted 
to miRNAs species in both PD and control patients. Relative to the whole small RNA content 
in the samples, miRNAs represented 90.39 % and 92.61 % of all mapped reads, respectively, 
in agreement to the small RNA composition found in human CNS tissue in reference studies 





with highest average expression in these samples, at least 4 miRNAs have been reported 
to be brain-specific (miR-181a-5p, miR-127-3p, miR-99b-5p, miR-9-5p) (Hinske et al., 2014; 
Lukiw, 2012), confirming the quality of the sequencing readouts acquired from the 
midbrain tissue of the analyzed individuals. 
A number of significantly deregulated miRNAs were identified by DE analyses with 
the small RNA sequencing data. When comparing the sequencing results from PD samples 
with the ones from the controls, 27 miRNAs were found deregulated – 20 of which are up-
regulated in the PD condition. This miRNA up-regulation in almost two-thirds of the DE 
species in PD samples is a phenomenon widely reported for neurodegenerative diseases 
like PD and AD (Gui et al., 2015a; Loring et al., 2001; Lukiw, 2007; Lukiw et al., 2012; Sethi 
and Lukiw, 2009; Starhof et al., 2019), and was also observed in a parallel study performing 
small RNA sequencing with CSF-exosomes of PD and control patients (Roser & Caldi Gomes 
et al, in preparation). This general miRNA upregulation might be related to a number of 
factors, for instance, the presence of a marked neuroinflammation and a high number of 
immune cells being recruited to the brain tissue of these patients (De Virgilio et al., 2016; 
Hunot and Hirsch, 2003; Kempuraj et al., 2016), as well as to the disruption of blood-brain 
barrier that takes place in PD and AD brains (Desai et al., 2007; Gray and Woulfe, 2015; 
Kortekaas et al., 2005; Rite et al., 2007), which could also be a potential source for 
exogenous miRNAs (e.g., from blood cells) being transported to the brain tissue and 
captured by sequencing techniques. Remarkably, the opposite is reported for amyotrophic 
lateral sclerosis (ALS), where the miRNA machinery and biogenesis is impaired in the 
affected motor neurons, resulting in a global downregulation of miRNAs (Eitan and 
Hornstein, 2016; Emde et al., 2015). 
Overall, a high inter-individual variability is observed for small RNA expression 
patterns even within conditions (portrayed in the heatmap from Figure 7), indicating that 
the disease state does not correspond entirely to the expression levels of the identified 
small RNAs. These findings evidence a molecular variability seen throughout the datasets 
presented in this work and might indicate the presence of individual subtypes of the 
disease.   In order to explore the aforementioned inter-individual differences even further, 
a Bayesian hierarchical clustering was performed with the miRNA expression data of a 





duration, PMI for tissue extraction and neuropathological diagnosis. In accordance with the 
overall picture given by the miRNA expression heatmap, the PD samples present a high 
heterogeneity in terms of miRNA expression. The hierarchical clustering was able to 
identify three sub-clusters of samples, two of them presenting more obvious similarities 
for miRNA expression levels within patients. Nevertheless, there seems to be no clear 
correlation for any of the clusters with the clinical features. Very similar findings were 
observed in PD CSF in a concomitant study conducted in this laboratory (Roser & Caldi 
Gomes et al., in preparation). These results indicate a potential pathological diversity at the 
molecular level that is reflected by miRNA expression. Interestingly, this diversity appears 
to result in a clinical Parkinsonism phenotype that does not permit to deduce the molecular 
background. 
Next, aiming to identify potential discriminative miRNAs between disease states, 
the small RNA sequencing results were employed in the development of an iterative 
feature analysis based on machine learning approaches with the miRNA expression data. A 
variable ranking was built for the selection of candidates that are more efficient in 
classifying disease states. Interestingly, four of the candidates identified as potential 
discriminative signatures were also found deregulated in DE analyses (namely, miR-29a-3p,  
miR-223-3p, miR-29c-3p, let-7g-5p), suggesting an important role of these miRNAs both in 
the context of PD pathophysiology and also as potential diagnostic biomarkers for PD. In 
addition, these candidates have been frequently found in altered levels in biomarker 
studies using body fluids of PD / controls patients (as reviewed in Roser et al., 2018), adding 
another level of evidence to the importance of these candidates in the context of PD.  The 
mechanistic relevance of these and several other DE miRNAs found here was explored in 
the context of PD pathology in subsequent experiments of this work. Ideally, replication 
studies both in midbrain samples and in circulating body fluids from independent patient 
cohorts would be required for the verification of the biomarker potential of the 
aforementioned candidates. 
In addition to the bioinformatical analyses, a thorough literature screening was 
performed using the DE miRNAs found in the present study in the context of neuronal-
related processes, neurodegeneration and other related processes. A list of all the searched 





deregulated miRNAs identified here were already reported to play an important role in 
dopaminergic neuronal function and/or PD pathology (Batistela et al., 2017; Caggiu et al., 
2018; Chi et al., 2018; Ghanbari et al., 2016; Lin et al., 2019; Singh and Sen, 2017; Wang et 
al., 2017; Xie et al., 2017). A number of these miRNAs have also been identified as putative 
circulating biomarkers in dozens of PD and AD studies up to now (extensively reviewed by 
three recent publications (Batistela et al., 2017; Mushtaq et al., 2016; Roser et al., 2018b)). 
Several of the deregulated miRNAs are linked to key-terms that include aging, 
neurodegeneration and brain injury (Dluzen et al., 2017; Gaudet et al., 2016; Goedeke and 
Fernández-Hernando, 2014; Kangas et al., 2017; Kim et al., 2016; Li et al., 2013a; Mo et al., 
2016; Xie et al., 2017) and neurogenesis, neuronal development and differentiation (Basak 
et al., 2016; Oh et al., 2018; Pieczora et al., 2017; Pons-Espinal et al., 2017; Qu et al., 2019). 
Another search category with a considerable number of hits for the DE miRNAs is 
inflammatory/immune response (Cardoso et al., 2012; Ge et al., 2016; Haneklaus et al., 
2013; Lambert et al., 2018; Sawant et al., 2015; Thome et al., 2016; Wu et al., 2018). More 
than a third of the miRNAs found up-regulated in the PD condition has been previously 
linked to processes related to immune response and inflammation, possibly indicating a 
feedback regulatory mechanism responding to the neuroinflammation observed in PD. The 
aforementioned processes are of extreme importance in PD pathology and progression and 
are discussed in more detail in section 4.4. It is important to highlight that postmortem 
midbrain samples are employed in this work, exclusively. Thus, the changes in miRNA 
expression (and also for the further molecular elements analyzed here) must reflect a very 
advanced stage of the PD pathology. Therefore, the relevance of the identified candidates 
for the pathogenesis of the disease has to be interpreted with caution. 
 
4.3 Pathway enrichment analysis reveals important biological roles for the targets of 
differentially expressed miRNAs in the context of PD 
Aiming to explore the functional role of the deregulated miRNAs both in neuronal 
function and homeostasis, as well as in neuropathological states, pathway enrichment 
analyses were conducted with experimentally validated targets of the deregulated miRNAs 





number of potential miRNA-mRNA pairs offered by computational target prediction 
(usually based on prediction by nucleotide complementarity), but offers the highest level 
of evidence for enriched biological processes and excludes the bias of non-canonical miRNA 
pairing or imperfect seed match that would not lead to any relevant biological consequence 
to the cell or organism (Agarwal et al., 2015; Friedman et al., 2008; Garcia et al., 2011). The 
enrichment analyses were conducted for targets of up- and down-regulated miRNAs 
individually. 
For up-regulated targets, the significantly enriched biological processes were 
characterized as neuron-related (32%), nucleus/chromosome related (30%) and 
cytoskeleton/cell growth-related (20%) (as the most representative GO categories). These 
findings indicate an important involvement of the up-regulated candidates in neuronal 
processes and also suggest that several of these miRNAs are likely originated in neurons, 
fitting well with the RNA samples of midbrain source analyzed here. Moreover, midbrain 
tissue biopsies contain a variety of neuronal and glial cell types (La Manno et al., 2016), 
which are likely accounting to the different categories annotated for the regulated miRNAs 
(depicted in figure 10). The top 5 most significant biological processes are related to 
regulation of cell proliferation, differentiation, cell cycle and neurogenesis, well in line with 
the results retrieved by the literature screening (Basak et al., 2016; Oh et al., 2018; Pieczora 
et al., 2017; Pons-Espinal et al., 2017; Qu et al., 2019). Remarkably, cell proliferation- and 
cell cycle-related proteins are known to play an important role also in the survival and 
maintenance of mature neurons (Herrup and Yang, 2007; Omais et al., 2018). Aberrant cell 
cycle was also reported to be intimately linked to apoptosis of post-mitotic neurons and 
neurodegeneration overall (Feddersen et al., 1992; Heintz, 1993). Interestingly, the 
regulation of targets related to cell proliferation and cell death seems to happen in both 
directions, being enriched for both up- and down-regulated miRNAs. That might indicate 
that the enrichment on the aforementioned categories might be related both to a response 
to the neurodegenerative processes occurring in the PD-affected brains, as well as reflect 
an impairment of mechanisms related to cell maintenance and survival leading to the 
neurodegeneration in PD.  More to that, regulation of cell death and  apoptotic process also 





providing further evidence for the involvement of these candidates in (or as a response to) 
the cell death occurring in PD midbrains (Kim et al., 2016; Li et al., 2013a; Xie et al., 2017).  
On the other hand, for the target of PD down-regulated miRNAs, the majority of the 
enriched GO terms belong to nucleus/chromosome-related processes (26%), 
cytoskeleton/cell growth-related processes (24%) and vesicular-related processes (19%). 
Interestingly, no enriched processes seem to be directly related to neuronal processes for 
the validates targets of PD down-regulated miRNAs. It’s important to account, though, that 
the number of down-regulated miRNAs in the PD condition is almost 3 times smaller than 
the up-regulated category, which consequently decreases the number of analyzed targets 
substantially. Some of the enriched biological processes seem to be related to 
mitochondrial mechanisms (7%), which also have fundamental implications in PD 
pathophysiology (Bose and Beal, 2016; Liu et al., 2017; Rocha et al., 2018). When analyzed 
individually, the biological processes enriched for the targets of down-regulated miRNAs 
are mostly related to the regulation of gene expression, transcription / RNA metabolism 
and regulation of biosynthetic processes, in line to what was observed for the results from 
the up-regulated miRNAs. Interestingly, GO terms related to apoptotic process and cellular 
response to stress figure among the enriched categories for the targets of down-regulated 
miRNAs, indicating that a possible insufficient miRNA regulation of stress- and apoptotic- 
related genes might be taking place for some of the identified candidates.  
In general, for the functional annotation of miRNA targets, it is important to 
consider that RNA material from a diversity of cells populating the analyzed midbrains was 
used for the sequencing. Thus, the enriched biological processes annotated for miRNA-
targets are reflecting cellular changes not only of neurons but also of glial and immune cells 
present at the analyzed tissue. This is especially important since a massive activation of the 
immune response was observed when analyzing the transcriptomics results for these 
samples (as discussed in section 4.4). As many of the most significant pathways enriched 
for targets of the deregulated miRNAs were related to cell proliferation and cell cycle and 
positive regulation of cellular biosynthetic processes, it is likely that several of the enriched 
pathways are related not only to the apoptosis of dopaminergic cells but also to an immune 
cell proliferation taking place in the PD-affected brains, for example(Hirsch and Hunot, 





2019; Rea et al., 2018; Viviani, 2004). To a certain extent, the aforementioned findings 
indicate a disturbance in the homeostatic state of the cell populations present in the 
analyzed midbrains and might reflect possible cellular responses to dopaminergic insults 
and the neurodegenerative events taking place at the PD-affected midbrains. The exact 
events happening at the transcriptomic and proteomic levels and detailed miRNA-mRNA 
interaction pairs were further explored in subsequent steps of this work. 
 
4.4 Transcriptomic profiling documents dopaminergic depletion and indicates an 
important inflammatory reaction in PD midbrains 
Aiming to explore the gene expression patterns in the analyzed samples, 
transcriptomic profiling through RNA sequencing and subsequent DE analyses were 
performed. In comparison to the DE results from miRNA expression depicted above, a much 
higher number of genes are found significantly deregulated in the transcriptomics analysis. 
Following pre-defined cut-offs, a total of 1452 transcripts were found altered when 
comparing PD samples to controls. Similar to the miRNA data, the majority of the 
deregulated candidates were found up-regulated in the PD condition, accounting to 67.1% 
of the significant results (975 transcripts). Furthermore, also similar to the findings of 
miRNA DE analyses, a rather high inter-individual variability in gene expression is observed. 
Nevertheless, in spite of some individuals presenting a general gene expression that differs 
from the other subjects within their disease state group, the majority of the PD patients 
seem to present an inversed pattern of expression for the genes found DE in comparison 
to the control subjects (as shown in heatmap from Figure 12). Moreover, the control group 
presents more homogeneous patterns of gene expression within subjects, while the PD 
once again presented a much higher expression heterogeneity, as observed in the 
hierarchical clustering analyses done with the miRNA data. That might be due to the fact 
that the postmortem midbrain samples used as controls here are obtained from patients 
that died from a variety of diseases but presented no neurological disorder besides age-
related changes. Remarkably, the opposite has been found in CSF studies in PD conducted 
in this lab, where controls presented a higher variability in miRNA expression (Roser & Caldi 





samples (in comparison to 15 analyzed here). Taken together, these findings support the 
concept that idiopathic PD is not a uniform disorder regarding its molecular pathogenesis 
and that there may exist multiple pathogenic subgroups among the affected subjects 
(Dexter and Jenner, 2013b; Johnson et al., 2019). 
In order to verify the functional role of the deregulated transcripts and explore the 
pathophysiological events taking place in the midbrains of the analyzed patients, pathway 
enrichment analyses were performed with the DE results for transcriptomics experiments, 
considering up-and down-regulated transcripts separately. The results for transcripts found 
down-regulated in PD revealed enrichment for dopamine-related biological processes, 
indicating that dopamine biosynthesis and dopaminergic transmission are indeed depleted 
in the patient samples, as expected for midbrain PD pathology (Dauer and Przedborski, 
2003a; Langston et al., 1983). The annotated genes for the enriched categories included 
key players for dopamine metabolism and function, for instance, tyrosine hydroxylase (TH), 
Dopa decarboxylase (DDC), dopamine transporters (SLC6A3 and SLC18A1) and dopamine 
receptor D2 (DRD2). Further, dopamine-related GO processes retrieved included 
locomotory behavior, learning, social behavior and dopamine biosynthetic process per se, 
all annotated for down-regulated genes in the PD condition. Moreover, KEGG pathways 
analyses retrieved Parkinson’s disease as the third most significant pathway for down-
regulated transcripts in PD samples. The term dopaminergic synapse is also enriched for 
those transcripts. Interestingly, the most significant KEGG pathway for PD down-regulated 
genes was the metabolic pathway. Although the enriched term is rather unspecific, 
metabolic dysfunctions, in general, have been often linked to PD pathology previously (Fai 
Poon et al., 2005; Hoepken et al., 2007; Huang et al., 2007; Perry et al., 1982; Polito et al., 
2012).  Dopaminergic neurons are also known to be especially sensitive to metabolic 
alterations, oxidative stress and mitochondrial dysfunction, for example (Anandhan et al., 
2017; Dexter and Jenner, 2013b; Greenamyre et al., 1999; Hauser and Hastings, 2013; Lin 
and Beal, 2006; Winklhofer and Haass, 2010). Another interesting enriched pathway for 
down-regulated transcripts in PD is annotated for genes playing a role in ribosomal 
processes. Coincidentally, it figures as the second most significant KEGG pathway for PD 
down-regulated transcripts, matching the strong enrichment for biological processes 





up-regulated miRNAs in PD (and consequent down-regulation of their targets). Similarly, 
processes related to the translational machinery figure at the top of the list of significantly 
enriched GO terms for PD down-regulated transcripts. Those findings support the 
connection between the miRNA and gene expression datasets and encourage the 
integrative efforts for the multi-omics approaches presented in this work. Overall, the 
dopamine-related enrichment results presented here indicate that molecular events 
related to dopaminergic pathology were indeed captured in the present experiments and 
is also an indicator for the quality of sample preparation and sequencing and for the 
plausibility of the results obtained.  
Remarkably, for genes up-regulated in the PD samples, the pathway enrichment 
results are predominantly related to a marked inflammatory response and immune system 
activation taking place in the patient midbrains. Eight out of the top 10 most significant GO 
terms enriched for those genes are directly or indirectly related to the immune / 
inflammatory response. Actually, the GO terms entitled inflammatory response and innate 
immune response figure at the very top of the list. Similarly, the vast majority of the KEGG 
pathway enrichment results are either related to immune system activation or to a variety 
of infectious diseases – probably due to the fact that the pathways for that kind of diseases 
also present a massive enrichment for genes related to immune cell activation and 
inflammation, as observed in the PD midbrains analyzed here. 
In more detail, highly significant enriched GO terms included, for example, 
interferon-gamma (IFNγ) mediated signaling, positive regulation of interferon type I 
production and positive regulation of NF-kappa B (NFKB) activity/signaling, processes 
intrinsically related to both adaptative and innate immune response (Dev et al., 2010; 
Kopitar-Jerala, 2015; Le Page et al., 2000). These processes have also been extensively 
linked to aging and neurodegeneration previously (Kaltschmidt et al., 1993; Kempuraj et 
al., 2016; Nazmi et al., 2019; Rea et al., 2018; Taylor et al., 2018; Viviani, 2004). In fact, 
NFKB signaling has been considered as the culprit of the so-called “inflammaging”, since 
this pathway seems to regulate immune and inflammatory responses at the cellular level 
both in aging and in age-related disorders (Balistreri et al., 2013; Salminen et al., 2008). An 
important study described an intense inflammatory reaction and dopaminergic cell damage 





(Castaño et al., 2002). Interestingly, lipopolysaccharide-mediated signaling pathway also 
figures among the enriched GO terms for PD up-regulated genes.  
There is also ample evidence for the participation of inflammatory cytokines in the 
pathophysiology and progression of PD. Neuroinflammatory and increased immune activity 
are known to contribute to the cascades of mechanisms that result to the 
neurodegeneration in PD (Hirsch and Hunot, 2009; Hunot and Hirsch, 2003; McGeer et al., 
1988a). Moreover, several postmortem studies have found a substantial increase of 
proinflammatory cytokines in parkinsonian brains (Imamura et al., 2003; Mogi et al., 1996a, 
1996b, 1996c; Nagatsu and Sawada, 2005; Sawada et al., 2006). Interestingly, the 
infiltration/activation of immune cells and marked neuroinflammation have been 
considered as aggravators of the disease, taking place at late stages of the 
neurodegenerative pathology in PD (Johnson et al., 2019; Maetzler et al., 2007; Menza et 
al., 2010). Oppositely, very early glial changes in PD brains seem to be related to αSyn 
deposition and a resultant astrocytic dysfunction (rather than microglia 
activation/leucocyte infiltration) (Gu et al., 2010; Halliday and Stevens, 2011; Johnson et 
al., 2019; Lee et al., 2010). These findings indicate that the marked changes in 
neuroinflammatory markers identified by us and the above-referred postmortem studies 
are most likely related to end-stage changes in PD-affected brains. 
Furthermore, a handful of studies have specifically implicated the cytokines NFKB 
and IFNγ – especially important in the context of our transcriptomic findings -  in PD 
pathophysiology. Mogi and colleagues found elevated levels of both NFKB and IFNγ in the 
postmortem brain tissue (substantia nigra, caudate nucleus and putamen) of PD-affected 
brains (Mogi et al., 2007). Furthermore, increased levels of IFNγ were reported to induce 
both a progressive degeneration of neurons in the nigrostriatal system and calcification of 
the basal ganglia (Chakrabarty et al., 2011). Another study pointed to the involvement of 
IFNγ in microglial-mediated dopaminergic neurodegeneration taking place in PD brains 
(Mount et al., 2007). Microglial activation seems to be closely related to the nigral 
degeneration in PD. They seem to produce deleterious effects to dopaminergic neurons by 
the release of multiple cytotoxic mediators, leading to a chronic and progressive 
neuroinflammatory state that directly influences the dopaminergic neurodegeneration 





of extensive dopaminergic degeneration in PD midbrains (Langston et al., 1983, 1999; 
McGeer et al., 1988a). Additionally, reactive microglia were shown to be highly detrimental 
to dopaminergic neurons in in vitro/in vivo models of PD  (Chen et al., 1998; Le et al., 1995, 
2001). Others showed that peripheral immune cells might also take part in the 
neuroinflammation occurring in PD. Cytotoxic CD4+ and CD8+ T lymphocytes were found 
in increased amounts in the substantia nigra of PD patients and, less extensively,  in the 
substantia nigra of AD-affected brains (McGeer et al., 1988a).  A subsequent study also 
showed that lymphocyte infiltration powered the dopaminergic degeneration in a mouse 
model of PD (Brochard et al., 2008). Similarly, postmortem studies identified increased 
amounts of T cells throughout AD-affected brains (Togo et al., 2002). Interestingly, 
immunostaining approaches revealed that cytotoxic lymphocytes cells are located close to 
blood vessels and also in the vicinity of neuromelanin-positive dopaminergic neurons in 
postmortem PD midbrains, suggesting that these immune cells are able to penetrate the 
brain from the bloodstream through the brain parenchyma, and that they might effectively 
interact with the degenerating dopaminergic neurons in those regions (Brochard et al., 
2008). The insults promoted by microglial and other immune cells in PD could be mediated 
by oxidative damage resultant from the cytotoxic activity of these cells, to which 
dopaminergic neurons are very sensitive (Hirsch and Hunot, 2009). However, other 
mechanisms, e.g. neuro-glial gliapse formation and subsequent phagocytosis, could also be 
involved (Barcia et al., 2012). 
For the few enriched pathways not linked to immune/inflammatory reactions, some 
terms are also relevant and worth mentioning for the up-regulated transcripts found in PD. 
The GO term entitled positive regulation of GTPase activity is also enriched for these 
transcripts and has been object of intense study by our group. The Rho family of GTPases, 
for example, are involved in several crucial neuronal processes including actin dynamics, 
axon growth, stabilization and guidance and synaptic plasticity. Some of these players and 
related interactors (e.g., RhoA; CDC42; RAC1; ROCK) are known to be important regulators 
of neuronal death, axon de- and regeneration, for example (Bustelo et al., 2007; Koch et 
al., 2018; Ridley, 2016). Preclinical studies have also shown that inhibiting the activity of 
these kinases could prevent degeneration and promote regeneration in in vitro and in vivo 





Additionally, KEGG pathways for apoptosis and MAPK signaling pathways are both 
enriched for the PD up-regulated transcripts. These pathways are very likely reflecting the 
neurodegenerative processes and alterations in mechanisms related to cell survival taking 
place in the midbrains of the patients (Dauer and Przedborski, 2003a; Dexter and Jenner, 
2013b). Furthermore, positive regulation of transcription (and related) GO terms are also 
enriched. The MAPK signaling cascade is not only linked to cell survival and stress 
responses, but also to the regulation of gene expression, for example (Cargnello and Roux, 
2011). These findings once again match the positive regulation of gene expression, RNA 
biosynthetic processes and cell response to stress found enriched for the deregulated 
miRNAs, suggesting once again an interplay between the miRNA and the gene expression 
data. 
All in all, the functional annotation with the transcripts found up-regulated in the 
PD condition showed that the inflammatory and immune responses are major processes in 
the physiopathology in the affected patients.  In fact, there is a present consensus that 
neuroinflammation is an important factor in the context of PD (Hirsch and Hunot, 2009; 
Johnson et al., 2019; Kalia and Lang, 2015). Neuroinflammation has also been considered 
also a predictive feature for the development of cognitive decline and non-motor 
symptoms in PD, another indication for its role in intensifying the dopaminergic damage, 
directly influencing the progression of the disease (Maetzler et al., 2007; Menza et al., 
2010). As we have analyzed postmortem midbrain samples from patients presenting PD 
pathology at advanced stages, it is not possible to determine whether the 
neuroinflammation-related mechanisms contributed to the initiation of the disease. 
Nonetheless, our transcriptomics findings provided additional evidence that 
neuroinflammatory changes are indeed playing a major role in the pathophysiology of PD, 
at least in advanced stages. As a matter of fact, end stages of the disease are the most 
complicated to target therapeutically, and dramatically burden the quality of life of PD 
patients (Lim et al., 2009). Therefore, exploring whether the attenuation of the 
neuroinflammation in advanced stages of PD could lead to any improvements to disease 
progression would be essential, and might lead to promising novel therapeutic strategies 






4.5 Proteomic profiling reveals enrichment in PD-related pathways matching the 
transcriptomic results 
In order to explore the differences in protein expression in the analyzed midbrain 
samples, mass spectrometry experiments were performed, followed by DE and functional 
enrichment analyses. In comparison to the small RNA and transcriptomics datasets, only 
proteins uniquely identified within all analyzed samples are considered for the 
quantitation, making the coverage and the size of the proteomics dataset substantially 
smaller. After peptide mapping and protein quantitation, a total of 2,257 proteins were 
uniquely identified, and DE analyses revealed 127 significantly regulated proteins when 
comparing the PD condition to the respective controls. In line with what was observed in 
the previous datasets, the majority of the DE proteins (69%) were found up-regulated in 
the PD samples (87 proteins), while only 31% of the significantly regulated proteins (40 out 
of 127) were down-regulated in PD. Also similar to the small RNA and transcriptomics, the 
protein expression data presented high inter-individual differences within subjects. The 
protein expression data shows a high inter-individual variability even within 
diseased/control cohorts (Figure 13). Similar findings were observed for all approaches 
employed here and again suggests multiple molecular subtypes in PD patients. 
Expectedly, the DE results for the protein expression data revealed a down-
regulation in TH - the most robust marker for dopamine metabolism and dopamine 
depletion in PD (Molinoff and Axelrod, 1971; Perez et al., 2002) - in line with the TH down-
regulation found for the transcriptomics experiments. Remarkably, functional annotation 
revealed the pathway immune effector process as significantly enriched for the DE proteins 
in PD, matching the massive immune/inflammatory activation reported for the 
transcriptomics results. Several cytokines, immune mediators and receptors seem to be 
deregulated in PD, indicating that the alterations seen in the previous omics results 
presented here are also captured at the proteomic level. For instance, the category immune 
effector process was annotated for a variety of important genes that included CD47, C1QC, 
CHI3L1, LAMP2, RAB18 (full list portrayed in table 12). A strong enrichment is shown for 
the process entitled negative regulation of protein folding - the most significant of all 
enriched categories. Defects in protein folding and metabolism have been extensively 





(Dauer and Przedborski, 2003a; Ebrahimi-Fakhari et al., 2013; Ross and Pickart, 2004; Ryu 
et al., 2002; Selkoe, 2004). It is important to mention that the mechanisms for protein 
folding involve a multitude of players, but this particular category enriched in our 
proteomics DE results (GO term ID: 1903333) is composed of only 5 genes (BAG5, PDCD5, 
PDCL, SNRNP70, ST13) – 2 of which are present in our dataset (SNRNP70, ST13). ST13 and 
SNRNP70 are both found up-regulated in PD. ST13 (encoding for the Hsc-70 interacting 
protein) is a co-chaperone that activates the heat-shock protein 70 (HSP70), a chaperone 
known to reduce αSyn aggregation and toxicity (Klucken et al., 2004; Nollen et al., 2001). 
Alterations in levels of ST13 have been already reported in PD blood, with decreased levels 
of this protein being found in PD patients in comparison to controls and to AD patients 
(Scherzer et al., 2007). Although ST13 levels in our proteomics study are opposed to the 
ones reported for PD blood, a compensatory mechanism in response to increased αSyn 
aggregation may be involved in the up-regulation of ST13 in PD midbrains.  SNRNP70 (Small 
Nuclear Ribonucleoprotein U1 Subunit 70), a protein originally involved in spliceosome 
formation (Will and Lührmann, 2001), is reported to selectively associate with Tau 
neurofibrillary tangles and aggregate in the brains of AD patients (Bai et al., 2013). 
SNRNP70 was also found in increased levels in the brains of AD patients through proteomics 
approaches (Diner et al., 2014; Hales et al., 2016). Tau pathology has been increasingly 
implicated in synucleinopathies, Lewy body formation and PD pathology (Ishizawa et al., 
2003; Wills et al., 2010; Zhang et al., 2018), reinforcing the relevance of the findings 
presented here. 
Another important enriched category for the DE proteins in PD is entitled Oxidation-
reduction process. As discussed in section 4.4, oxidative damage is especially important in 
the context of dopaminergic degeneration in PD and may be responsible for the increased 
selective vulnerability of dopaminergic neurons (Anandhan et al., 2017; Dexter and Jenner, 
2013b; Hauser and Hastings, 2013; Lin and Beal, 2006). The presence of deregulated 
proteins annotated to these processes matches the previous datasets presented here and 
indicate that previously described pathological mechanisms are indeed captured by our 
multi-omics analysis. Up-regulated proteins in this category included MAOB, NADH-
ubiquinone oxidoreductase core subunits B3 and S2, CBR1, PRDX 1 and 6 – all of them also 





common to the pathway entitled organophosphate metabolic process. Table 12 encloses 
the list of all enriched pathways and annotated proteins. Interestingly, MAOB inhibitors 
have been reported to have neuroprotective effects for dopaminergic neurons. 
Furthermore, MAOB polymorphisms were associated with increased risk for PD 
development (Dezsi and Vecsei, 2017). Pre-clinical results motivated a number of clinical 
trials with MAOB inhibitors for PD. These candidates presented inconsistent results at the 
trials and have not been considered as clinically relevant for PD (Clarke et al., 2011; Olanow 
et al., 2009). Nevertheless, MAOB inhibitors are still considered as relevant in terms of PD 
pathomechanisms and have been object of a handful of recent studies (Bar-Am et al., 2015; 
Guo et al., 2016; Huleatt et al., 2015; Robakis and Fahn, 2015; Tong et al., 2017). Studies 
have also linked the activity of mitochondrial NADH-ubiquinone oxidoreductase to MTPT 
and MPP+ dopaminergic neurotoxicity, for example (Conn et al., 2001; Mizuno et al., 1986). 
The enriched pathways secretion by cell and vesicle-mediated transport contain several 
overlapping proteins, and despite being very broad pathways with thousands of involved 
proteins, the might be very relevant for PD pathology. Recent studies have suggested that 
both αSyn and Tau are propagated through neurons trans-synaptically, being secreted and 
uptaken by neurons via extracellular vesicles fueling the αSyn pathology spreading 
hypothesis and relating it to PD progression (Cheng et al., 2018; Gustafsson et al., 2018; 
Okuzumi et al., 2018; Vasili et al., 2019). Furthermore, several studies have also indicated 
an important synaptic dysfunction as one of the pathogenic mechanisms in PD, particularly 
in the early stages of the disease (Abeliovich and Gitler, 2016; Bagetta et al., 2010; Burke 
and O’Malley, 2014; Schirinzi et al., 2016). 
Overall, the functional enrichment results for the multi-omics experiments 
presented above showed several processes of importance in the context of PD, validating 
known pathways and providing evidence for the involvement of previously less-regarded 
pathomechanisms involved in PD (e.g. inflammatory responses). Efforts into integrating the 








4.6 Multi-omics integration identifies common pathways in matched datasets 
4.6.1 Integration of small RNA and transcriptomics 
In order to explore pathways of deregulation within the multi-omics studies 
presented here, a step-wise integration of the datasets was performed using the DE results 
for each of the techniques (miRNAomics, transcriptomics and proteomics). First, the 
integration of the small RNA and transcriptomics data was performed. After a 
computational target prediction for the DE miRNAs, both a bioinformatical tool 
(RRHO)(Plaisier et al., 2010) and a manual cross-correlation were performed in parallel for 
the identification of overlapping candidates. The discordant overlap between the two lists 
was retrieved in order to extract the valid miRNA-mRNA interacting pairs. The list of 
overlapping candidates contained potential pairs that would support hypotheses of miRNA 
regulation of gene expression in the samples (up-regulated miRNAs were considered for 
the retrieval of the respective down-regulated targets mRNA, and vice-versa). The RRHO 
algorithm was less stringent in the overlap retrieval since it used the full sequencing results 
including very lowly expressed transcripts and miRNAs that were manually disregarded for 
downstream analyses. Therefore, the number of transcripts and miRNAs identified there 
was much higher than in the manual cross-correlation (that considered cut-offs for fold 
change in expression and a minimum number of reads). Nevertheless, when comparing the 
results from both approaches, a big overlap is observed, with 22 out of the 23 DE transcripts 
found with the manual approach being also present in the RRHO output results. Therefore, 
the manual method was considered as a refinement of the automated bioinformatical 
approach. A final list of 22 transcripts and 9 miRNAs was thus considered for further steps 
(Figure 15B). Finally, in order to select the most relevant interacting pairs, the candidates 
were filtered according to the highest probability of conserved targeting (Friedman et al., 
2008). With that, twelve out of the 22 retrieved transcripts and all of the 9 miRNAs 
potentially regulating them were selected for validation of the sequencing results. The 
selected mRNAs included DHX57, RNF170, TMEM178B, BRWD1, ENTPD5, C7orf73, SOCS4, 
STEAP3, MIER2, FOXF1, RIMS1 and PPTC7. For the miRNAs, the selected candidates were 
the following: let-7i-5p; miR-26a-5p; miR-2018-5p; miR-424-5p; miR-29c-3p; let-7g-5p; 





The relevance of several of the selected miRNAs in processes as neurodegeneration, 
neuroinflammation and PD pathology was discussed in sections 4.2 and 4.3. For the 
selected DE transcripts, several of them have been studied in the context of 
neurodegenerative diseases. For example, SOCS4 (Suppressor of cytokine signaling 4), 
found in increased levels in PD in the transcriptomics results, is known to be involved in 
both JAK-STAT and PTEN-mTOR signaling pathways, influencing processes that include cell 
growth, apoptosis, survival, neuroinflammation and neurodegeneration (Nicolas et al., 
2013; Park et al., 2004, 2008, 2009; Sekine et al., 2018). In addition, an important study 
showed that deleting a protein of the same family of SOCS4 (SOCS3) promoted 
regeneration in optic nerve neurons in vivo (Smith et al., 2009). All members of the SOCS 
family share a central Src homology 2 (SH2) domain, as well as an extended SH2 domain 
and a C-terminal SOCS box (Palmer and Restifo, 2009). Interestingly, the triplet composed 
by  SOCS3/SOCS4/SOCS5 is reported to have a marked pair-wise homology (Duncan et al., 
2017), indicating the importance of these findings for in the context of neurode- and 
regeneration. Another important candidate is RNF170 (Ring finger protein 170), known to 
be involved in protein ubiquitination/degradation (Claessen et al., 2012; Nakamura, 2011). 
RNF170 seems to be especially important for the metabolism of inositol-1,4,5-triphosphate 
(IP3), and might thereby play a role in regulating autophagy-related mechanisms, a 
mechanism that plays an important role in PD pathology due to its involvement in protein 
and aggregate degradation (Anglade et al., 1997; Lu et al., 2011; Sarkar and Rubinsztein, 
2006; Williams et al., 2008; Winslow and Rubinsztein, 2011). Moreover, a study showed 
that a point mutation in the RNF170 gene is responsible for autosomal cases of sensory 
ataxia by impairing IP3-mediated Ca2+ signaling (Wright et al., 2015). The protein STEAP3 
(Six-Transmembrane Epithelial Antigen Of Prostate 3), a metalloreductase, also figures as 
an interesting candidate among the selected transcripts. It has been implicated in 
processes that include apoptosis and survival, and also in the regulation of inflammatory 
responses (Grunewald et al., 2012; Passer et al., 2003; Zhang et al., 2012). It has also shown 
robust pro-amyloidogenic properties in vitro, suggesting that it might influence protein 
aggregation also in PD (Roberts et al., 2017). Interestingly, STEAP3 is involved in iron 
homeostasis (Lambe et al., 2009) and can also regulate copper metabolism (Ohgami et al., 
2006). Both elements are known to play an important role in PD and have also been object 





2019; Maass et al., 2018; Montes et al., 2014). The final list of selected candidates 
(portrayed in Figure 15) was considered for the q-RT-PCR validation of the sequencing 
studies. The relevance of all validated candidates is further discussed in the subsequent 
sections. 
 
4.6.2 Integration of and transcriptomics and proteomics 
Similar to what was done with the small RNA and transcriptomics datasets, the 
overlapping DE results for transcriptomics and proteomics experiments were also explored 
in an integrative fashion. In this case, we looked for the concordant overlap between the 
coding mRNAs and their respective protein product (i.e. up- and down-regulated transcript-
protein pairs). Factors related to protein metabolism and kinetics (e.g., synthesis and 
degradation rates of proteins) were out of the scope of this study and were therefore not 
considered for the integrative analyses presented here, although they are likely to 
significantly contribute to the overall picture.  
Proteomics and RNA sequencing results are fundamentally very different, starting 
by the nature of the signals and the coverage of those techniques. That makes the 
comparison of quantitative values (in this case, counts and intensities) by bioinformatical 
pipelines rather challenging. Therefore, we decided to apply a manual cross-correlation 
method for the integration, similarly to what was done for the manual integration of the 
miRNA and transcriptomics data. The much smaller range of DE proteins (127) was also 
favorable for the employment of such an approach. As presented in section 3.11.2, the 
total number of uniquely identified proteins was more than 20 times smaller than the 
number of mapped transcripts. Therefore, several of the DE transcripts found in the RNA 
sequencing results did not have their respective protein product identified in the 
proteomics results. The opposite also happened, to a lesser extent. Overall, disregarding 
the validity of the interaction pairs (i.e. the directionality of the fold changes in expression) 
the integrative approaches applied here revealed that 30 candidates were found 
significantly regulated in both transcriptomics and proteomics experiments (around 24% of 
all the proteomics DE results). When considering the valid pairs with concordant fold 





integration of the transcriptomics and proteomics datasets. Seven of them presented up-
regulation in the PD samples (ATP6V1E1, C9ORF47, CD47, ACOT7, RPL35, SEC23A and 
RPN1) while six candidates were found down-regulated in PD, both in transcriptomics and 
proteomics (TH, DBT, CD200, RAB18, NIPSNAP3A UBE2L3). It is important to mention that 
the final list of candidates selected from the integration of transcriptomics and proteomics 
is currently being validated by Western Blotting and the results will not figure in the scope 
of this thesis. As discussed in sections 4.4 and 4.5, the presence of the dopamine marker 
TH among the down-regulated candidates in both datasets, as well as the present of 
coincidentally enriched pathways throughout the omics datasets (e.g. inflammatory 
response, metabolism- and apoptosis-related processes) provide additional reliability to 
the functional annotation presented for each approach. 
 
4.7. Validation of sequencing results in human midbrain tissue by q-RT-PCR 
4.7.1. miRNA data validation 
After integration and the final miRNA candidate selection (section 3.11.1), nine 
miRNAs were validated in the human midbrain tissue (upon fresh RNA isolation and reverse 
transcription for cDNA preparation). For the miRNAs found down-regulated in PD by 
sequencing experiments, all selected candidates (let-7g-5p, miR-20a-5p, miR-145-5p, miR-
98-5p) were successfully validated by q-RT-PCR, presenting the same expression 
directionality as observed in the sequencing. For the miRNAs found up-regulated in PD by 
small RNA sequencing, 2 out of 5 (let-7i and miR-29c) presented significant differences in 
the validation studies with a regulation in the opposite direction compared to what was 
observed in the sequencing. Similar findings with an opposing regulation of one and the 
same target from discovery to validation studies have been frequently reported in 
biomarker studies using PD body fluids (Roser et al., 2018b; Halbgebauer et al., 2016). A 
number of factors might influence the outcome of validation studies. For example, 
alternative splicing often leads to discordant results between sequencing and q-RT-PCR 
experiments (Nazarov et al., 2017). The sensitivity of the two methods might also be an 
issue. A study reported a sensitivity threshold for the validation of sequencing results by q-





possible for species presenting very low sequencing reads (<100 reads per species) (Cristino 
et al., 2011). In addition, the design of different commercially available primers and the 
number of amplified exons might also interfere with the validation of candidates identified 
by the sequencing. The opposing results presented here could be further explored by 
repeating the experiments with additional primers for the selected candidates, for 
example. Overall, the results showed that four out of the nine selected miRNA candidates 
were successfully validated by q-RT-PCR and concordant to the small RNA sequencing data.  
An overview of the biological relevance of all DE miRNAs is presented in section 4.4. 
For the validated miRNAs (let-7g-5p, miR-20a-5p, miR-145-5p, miR-98-5p), several of them 
have been implicated in neuronal- and neurodegeneration-related processes. A 
comprehensive study showed that let-7g-5p is among the top 40 highly expressed miRNA 
found in human brains (Shao et al., 2010). Deregulation of let-7g-5p has been also linked 
to neurodegenerative diseases. For instance, this miRNA has been included in a plasma 
biomarker panel of signature miRNAs able to distinguish AD patients from controls with 
high accuracy (Kumar et al., 2013). It has been also found significantly down-regulated in 
peripheral blood of Amyotrophic Lateral Sclerosis (ALS) patients (Liguori et al., 2018). Let-
7g-5p has also been shown be deregulated in PD models of αSyn overexpression (Asikainen 
et al., 2010), and the complementary strand of this miRNA, let-7g-3p, has been found 
differentially expressed in PD CSF (Gui et al., 2015a). Similarly, miR-20a-5p has been found 
in altered levels in both AD CSF and PD cortical brain regions (Chatterjee and Roy, 2017; 
Riancho et al., 2017). This miRNA is known to regulate neuronal differentiation (Cui et al., 
2016). Another of the validated miRNAs, miR-98-5p, has been extensively linked to AD. It 
has been shown to regulate amyloid β-peptide (Aβ) protein production (Li et al., 2016) and 
has been found in decreased levels in AD serum (Tan et al., 2014). Finally, miR-145-5p has 
been implicated in a variety of neuronal-related processes. For example, it is known to play 
a role in neuronal differentiation as well as to induce glial inflammatory insults (Jauhari et 
al., 2018; Li et al., 2013b). Remarkably, miR-145-5p is known to regulate, for example, 
microglia activation and astrocyte injury in models of cerebral stroke (Qi et al., 2017; Xie et 
al., 2017; Zheng et al., 2017), matching the intense inflammatory and immune response 





validated miRNA candidates as important regulators in neurodegenerative processes 
taking place in PD.  
4.7.2. Transcriptomics data validation 
Similarly, the mRNA candidates selected by the integration of miRNA and 
transcriptomics datasets (section 3.11.1) were validated by q-RT-PCR in the midbrain 
samples of PD and controls studied here. Seven of the selected candidates were found in 
up-regulated levels in PD by the RNA sequencing results. Out of these,  four mRNAs were 
successfully validated and presented the same pattern of regulation in the validation 
experiments. These were SOCS4, STEAP3, MIER2 and FOXF1. The relevance of the first two 
for PD pathology has been extensively discussed in section 4.6.1. MIER2 (Mesoderm 
induction early response protein 2) is a chromatin-binding transcript and is involved in 
histone deacetylation (Derwish et al., 2017), a process extensively linked to the 
development of neurodegenerative disorders as AD and PD (Abel and Zukin, 2008; Chuang 
et al., 2009; Fischer, 2014; Harrison and Dexter, 2013; Sharma and Taliyan, 2015; Stilling 
and Fischer, 2011). FOXF1 (Forkhead box protein F1) is an important transcription factor 
regulating embryonic development and is reported to play a role in dopaminergic 
differentiation through interaction with sonic hedgehog (SHH) (Peterson and Turnbull, 
2012; Wu et al., 2012).  
On the other hand, for the transcripts found down-regulated in PD by RNA 
sequencing experiments, none of the selected candidates presented significant differences 
in relative expression levels in the q-RT-PCR validation results. Nevertheless, all transcripts 
presented, on average, lower expression levels in PD samples when compared to controls. 
The same effect was observed several times both for the mRNA and the miRNA validation 
experiments. One plausible possibility is that the limited cohort size might influence the 
statistical power of the experiments presented here, being a technical limitation for the 
validation of the sequencing results. As discussed above (section 4.7.1), it is also worth 
mentioning that the different methods employed for discovery and subsequent validation 
of transcripts and miRNAs present obvious differences in sensitivity, what could account 
for the divergent findings presented here. Several factors are reported to influence 





of candidates presenting a low number of sequencing reads, primer design and differences 
in exonal region amplification might influence the outcome of validation studies (Cristino 
et al., 2011; Nazarov et al., 2017). Thus, similar to the miRNA validation, the transcriptomics 
validation results could also be further explored by repeating q-RT-PCR experiments with 
additional primers for the selected transcripts.  
In conclusion, a substantial number of the selected miRNA and mRNA candidates 
found DE in RNA sequencing experiments were successfully validated by q-RT-PCR. A 
number of the candidates also presented similar tendency for the expression levels in the 
validation studies in comparison to the sequencing results, but the results were not 
statistically significant - likely because of the aforementioned technical limitations of the 
methods employed here. Nevertheless, the patterns of the relative expression levels 
determined by q-RT-PCR were similar to the ones found in RNA sequencing experiments 
for the majority of the selected species. Interestingly, there was a good match for the 
validated miRNA-mRNA interacting pairs: down-regulated miRNAs in PD were successfully 
validated, and PD up-regulated transcripts – known targets of the validated miRNAs –   were 
also validated by q-RT-PCR. The valid interaction pairs validated here were the following: 
let-7g-5p/SOCS4; let-7g-5p/STEAP3; miR-20a-5p/MIER2; miR-20a-5p/FOXF1. Those 
findings indicate that these candidates are likely to play an important mechanistic role in 
the pathology presented by the affected patients. Further validation studies (e.g. 
immunoblotting) will be conducted with these and the additional candidates identified in 
integrative approaches. 
 
4.8. Validation of PD-deregulated miRNAs and transcripts in αSyn.A53T midbrains 
To complement our studies of human tissue, we compared the miRNA and mRNA 
expression results obtained in human midbrains with corresponding results from a 
transgenic mouse model of PD. For that, male mice overexpressing human αSyn containing 
the A53T mutation under the prnp promoter were employed. This mouse model 
reproduces a genetic (autosomal-dominant) form of PD, but it also resembles features of 
the idiopathic form of the disease, such as αSyn aggregation: Studies showed that the 





(Conway et al., 1998; Dauer and Przedborski, 2003a; Krüger et al., 1998). Thus, the 
αSyn.A53T mouse model is considered a useful tool to study synucleinopathies as PD. The 
transgenic mice develop a progressive and severe motor phenotype starting around 8 
months of age. The appearance of αSyn aggregate inclusions matches the onset of the 
motor impairments (Giasson et al., 2002). Here, we evaluated the expression levels of the 
human validated miRNAs and transcripts in different stages of the pathology presented by 
the transgenic mice. In summary, the aim of the animal experiments presented here was 
to verify whether the alterations observed in the human midbrain tissue correlate with the 
patterns found in the same cerebral region in the mouse model. Details about cohort 
design and experimental setups are described in sections 2.2.2.1 and 3.14. 
The miRNA validation in αSyn.A53T mice midbrains revealed that no significant 
alterations are observed in miRNA levels in early time points, indicating that deregulation 
of miRNA expression is likely linked to the development of the progressive motor 
phenotype presented in later stages. At an intermediate time point, the levels of two 
miRNAs are found significantly deregulated in the transgenic condition in comparison to 
control animals. miR-20a-5p is found down-regulated in transgenic animals – in line with 
the human findings - while miR-145-5p is up-regulated in those individuals, inversely to the 
expression presented in PD-affected human midbrains. At late stages of the αSyn pathology 
in the mice, the results seem to be more variable within the subjects of individual cohorts, 
potentially denoting a misbalance in the miRNA machinery in older animals. Another 
miRNA, miR-98-5p, presented significant changes in relative expression, being down-
regulated in the transgenic animal, also in line with the human results. 
For the mRNA validation, not only the human validated transcripts were considered 
for q-RT-PCR experiments, but an extended candidate selection was conducted (section 
3.14.2). In order to explore possible correlations in further pathological features presented 
by the transgenic mice in relation to the PD pathology in humans, a set of PD-related genes 
was also selected for validation experiments. The cut-off criterion for further-selected 
genes was that candidates must be significantly regulated in the human transcriptomics 
results. Classical genes previously described to be involved in PD pathogenesis and 
progression were retrieved from a comprehensive review (Kalia and Lang, 2015). In 





the analysis of 7.8 million SNPs in dozens of thousands of PD cases / over a million control 
cases) (Nalls et al., 2018). In the end, a total of 9 transcripts were additionally selected for 
the validation by q-RT-PCR. 
The mRNA validation results showed that most of the analyzed transcripts 
presented changes in relative expression at early and intermediate ages, suggesting that, 
at the transcriptomic level, pathological mechanisms related to the motor phenotype might 
start taking place very early in the course of the lifespan of these animals. No differences 
were observed for any of the genes at late time points, indicating that not only the 
pathology but also aging per se might cause changes in the expression level of the evaluated 
genes in control animals. Only one gene, MIER2 (extensively discussed above), presented 
significant differences discordant to the human results, being down-regulated in the 
transgenic animals at intermediate ages. For all the other genes presenting significant 
altered relative expression levels, the results were concordant with the human findings for 
the validated targets. Genes as SOCS4, HSPA1, PINK1, GALC, POLG1, RIMS1, DYRK1a and 
SQSTM1 presented elevation in relative expression levels in the transgenic animals either 
at 100 days of age or at 250 days of age (or for both in the case of PINK1 and DYRK1a. As 
discussed in previous sections, SOCS4 is involved in processes that include cell growth, 
apoptosis and survival, neuroinflammation and neurodegeneration, thus, showing to be 
relevant for the pathology and progression of PD (Nicolas et al., 2013; Park et al., 2004, 
2008, 2009; Sekine et al., 2018). HSPA1 is a member of the heat shock proteins and plays 
an important role in protein folding and degradation and is also linked to neuronal 
apoptosis (Leak, 2014; Mayer and Bukau, 2005). Another gene related to protein 
degradation is SQSTM1, important for the formation of autophagosomes and ubiquitin-
related protein degradation (Bjørkøy et al., 2005; Clausen et al., 2010; Isakson et al., 2013; 
Taillebourg et al., 2012). Defects in protein degradation are known to be important in the 
context of αSyn aggregation, LB formation and for PD pathology in general, indicating that 
these players might be relevant for the pathology related to the αSyn.A53T mutation.  
Furthermore, PINK1 is a classical PD gene and encodes a protein kinase important 
for mitochondrial function and energy metabolism, for example. PINK1 mutations are 
known to cause early-onset PD cases (Dagda et al., 2014; Lazarou et al., 2013; Narendra et 





regulation in the transgenic mice midbrains both at early and intermediate stages, 
indicating that mitochondrial dysfunction might be one of the pathomechanisms caused by 
the synucleinopathy presented by the animals. DYRK1a also presented elevated relative 
expression levels both at early and intermediate stages in transgenic animals. DYRK1a is 
known to interact with αSyn and enhance the intracellular formation of inclusions (Kim et 
al., 2006; Wegiel et al., 2011). It is also known to influence the survival of dopaminergic 
neurons upon development (Barallobre et al., 2014) and DYRK1a polymorphisms have been 
associated with the development of sporadic PD (Cen et al., 2016). Thus, our findings 
suggest that DYRK1a might play an important role in the development of the 
synucleinopathy in transgenic mice.  
Some studies linked defects in POLG1 to PD predisposition and progression (Gui et 
al., 2015a; Luoma et al., 2007). Moreover, a VUS in the POLG gene was even identified for 
one of the PD patients analyzed here. The results presented here provide an additional 
indication that POLG1 might indeed play a role in the neurodegenerative processes in PD. 
Another transcript found deregulated in αSyn.A53T midbrains was RIMS1, a member of the 
Ras superfamily and regulator of GTPase activity. GTPase activity is very relevant for axonal 
degeneration and PD progression (Koch et al., 2014, 2018; Tatenhorst et al., 2014; Tönges 
et al., 2011, 2012). RIMS1 is also important for regulation of neurotransmitter release 
(Coppola et al., 2001; Ohtsuka et al., 2002; Takao-Rikitsu et al., 2004), and the deregulation 
in the affected midbrains might be related to the dopaminergic dysfunction present in the 
PD-like pathology. Finally, GALC was also found in elevated levels in the transgenic animals 
at the early time point. GALC is an enzyme responsible for the lysosomal catabolism of 
myelin-containing lipids. Interestingly, alterations in myelination have already been 
reported in PD (Dean et al., 2016; Gattellaro et al., 2009). 
In conclusion, the findings presented here for the miRNA/mRNA validation in the 
midbrain of αSyn.A53T mice indicate that a substantial number of pathological processes 
are overlapping between the PD animal model and the pathology in humans. To a certain 
extent, our longitudinal study with the αSyn.A53T animals yielded insights to the pathology 
presented by the transgenic animals upon aging and indicated a satisfactory validity of the 
model in regard to the miRNA/mRNA expression patterns observed in PD-affected 





conducted validation study presented limited cohort numbers and strong outlier values 
have been excluded from the analysis, decreasing the statistical power of the analyses. 
Several of the analyzed transcripts/miRNAs presented a high intra-cohort relative 
expression variability, which could possibly be ameliorated with the inclusion of more 
animals. Additional animals were sacrificed by the time of the experiment execution, and 
the repetition of the presented experiments in bigger cohorts would provide stronger 





5. Concluding remarks 
The experiments conducted in the course of this doctoral thesis demonstrated that 
the use of high-throughput omics techniques allows the generation of comprehensive 
datasets for the exploration of molecular pathomechanisms of complex diseases, such as 
neurodegenerative disorders. Exploring the molecular events taking place in PD-affected 
brains is fundamental for better understanding the pathogenesis and progression of the 
disease and for the development of novel therapeutic avenues for PD. Nevertheless, results 
from post-mortem analyses always have to be put into context of an advanced disease 
stage. 
Here, several levels of deregulation were identified across multi-omics datasets in 
human midbrains affected by PD. Important players and molecular networks that seem to 
be relevant for advanced stages of PD pathology were revealed: we showed that a marked 
inflammation and immune response activation takes place in the analyzed midbrains, in 
addition to defects in protein degradation and metabolic dysfunctions. Our data thus 
strongly suggest that neuroinflammation may be a veritable therapeutic target, at least in 
advanced stages of the disease. 
Furthermore, we have been especially interested in the miRNA regulation of gene 
expression in PD. We identified and validated four miRNAs (let-7g-5p, miR-20a-5p, miR-
145-5p, miR-98-5p) in postmortem PD midbrains that have been previously linked to 
neurodegenerative / neuroinflammatory processes, providing additional evidence for the 
importance of these targets in the context of PD pathology. Furthermore, our multi-omics 
analyses allowed not only the profiling of miRNA expression patterns but also to verify the 
expression of miRNA direct targets and their protein products, providing insightful 
evidence for the participation of miRNAs in the neurodegenerative processes linked to the 
disease. Remarkably, miRNA-mRNA interacting pairs were identified and validated in the 
present samples (let-7g-5p/SOCS4; let-7g-5p/STEAP3; miR-20a-5p/MIER2; miR-20a-
5p/FOXF1). These pairs are likely to play an important mechanistic role in the pathology 





All in all, our approaches also evidence that efforts into optimizing the integration 
of large scale high-throughput datasets are absolutely required for the meaningful 
treatment and exploration of the data. 
Another important aspect shown here is that PD patients present a high inter-
individual variability for the expression of all types of molecular elements analyzed in our 
study, suggesting that patients with similar clinical phenotypes may have different 
molecular phenotypes. Moreover, our results also provided additional evidence for known 
pathomechanisms in PD (such as the aforementioned inflammatory changes, oxidative 
stress and metabolic dysfunctions). miRNAs possibly mediating these alterations were 
identified in our study and should be further validated in larger human cohorts as well as 
in animal models as therapeutic targets. Therefore, our findings might contribute to the 
exploration of novel disease-modifying avenues, which may increase the chances of 
attenuating disease progression. 
Finally, we have also assessed the validity of the prnp. αSyn.A53T mouse model of 
PD in terms of the overlap in miRNA and mRNA expression with human pathology. A 
number of correlating results were identified in our longitudinal animal study, providing 
insight into the time course of pathological changes in the animal brains upon aging that 
are similar to the ones occurring in human PD patients.  
All in all, the findings presented in this thesis yielded new insight in the 
pathomechanisms involved in PD, may contribute to the development of novel 
experimental PD models based on miRNA regulation and could establish promising new 






Parkinson’s Disease (PD) is the second most prevalent and fastest-growing 
neurological disorder. The number of affected individuals is expected to double in the next 
20 years. The exact molecular mechanisms underlying PD pathology are not completely 
understood. In addition, its diagnosis mainly relies on clinical criteria related to the 
characteristic motor dysfunction in PD. Since the symptoms only start to appear at 
advanced stages of the nigrostriatal degeneration characteristic in PD, there is a strong 
limitation for the promotion of therapeutic strategies that might be able to change the 
course of the disease. Allied to that, the limited regenerative capabilities of cells in the CNS 
complicate the development of restorative treatments. Therefore, understanding the key 
pathogenetic mechanisms of PD is fundamental for the the development of disease-
modifying therapies. Profiling the expression of molecular element such as miRNAs, 
transcripts and proteins in brains affected by PD might reveal a series of pathological events 
taking place both at cellular and systemic levels in the course of the disease.  
The present doctoral thesis aimed to analyze midbrain tissue samples from a cohort 
of PD patients and controls in a multi-omics set of experiments, looking into the genetic 
background of the selected subjects, as well as characterizing the expression patterns of 
miRNAs, transcripts and proteins on those samples. Here, several levels of deregulation 
were identified across multi-omics datasets in human midbrains affected by PD. Important 
players and molecular networks that seem to be relevant for advanced stages of PD 
pathology were revealed: we showed that a marked inflammation and immune response 
activation takes place in the analyzed midbrains, in addition to defects in protein 
degradation and metabolic dysfunctions. Our data thus strongly suggest that 
neuroinflammation may be a veritable therapeutic target, at least in advanced stages of 
the disease. In addition, we identified not only deregulated transcripts and proteins linked 
with pathological processes, but also miRNAs that might be involved in the pathophysiology 
of the disease. Finally, we have also assessed the validity of the prnp. αSyn.A53T mouse 
model of PD in terms of the overlap in miRNA and mRNA expression with human pathology. 
A number of correlating results were identified in our longitudinal animal study, providing 
insight into the time course of pathological changes in the animal brains upon aging that 
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9. List of abbreviations 
 
AD: Alzheimer’s Disease 
AGO: argonaute proteins 
ALS: Amyotrophic Lateral Sclerosis 
ANOVA: Analysis of variance 
BP: Biological process 
CNS: Central nervous system 
CSF: cerebrospinal fluid 
DA: Dopamine 
DAG: Directed Acyclic Graph 
DAVID: Database for Annotation, Visualization and Integrated Discovery 
DDC: Dopa decarboxylase 
DE: differential expression / differentially expressed 
DNA: deoxyribonucleic acid 
FC: fold change 
FDR: false discovery rate 
GO: Gene ontology 
HD: Huntington’s Disease 
IFNγ: interferon-gamma 
KEGG: Kyoto Encyclopedia of Genes and Genomes 
LB: Lewy Bodies 
LBD-BS: Lewy body disease, brain stem predominant 




LBDE: Lewy body disease, early-neocortical 
LBD-N: Lewy body disease, neocortical 
L-DOPA: L-3,4-dihydroxyphenylalanine 
LNA: locked nucleic acid 
LPS: lipopolysaccharide 
MLPA: Multiplex Ligation-dependent Probe Amplification 
PBS: Phosphate buffered saline 
PD: Parkinson’s Disease 
PMI: Post-mortem intervals 
q-RT-PCR: Quantitative real-time polymerase chain reaction 
RISC: RNA-induced silencing complex 
RNA: ribonucleic acid 
RRHO: Rank-Rank Hypergeometric Overlap 
RUV: Removal of unwanted variances 
SEM: Standard error of the mean 
SHH: sonic hedgehog 
STN: Subthalamic nucleus 
SWATH: sequential window acquisition of all theoretical fragment ion spectra 
TH: tyrosine hydroxylas 
UK: United Kingdom 
UTR: untranslated regions 





Herewith I declare, that I prepared the Doctoral Thesis “Multi-omics analysis 
of human brain tissue and an animal model of Parkinson’s disease” on my 
own and with no other sources and aids than quoted.  
 
Göttingen, September, 2019                Lucas Caldi Gomes 
 
 
 
 
 
 
 
 
 
 
 
 
